US 20060166892A1. ( 19 ) United States ( 12 ) Patent Applicati0n Publicati0n mm Pub. N0. : US 2006 / 0166892 A1. . Alvarez et al. ( 43 ) Pub. Date : Jul. 27 , 2006 ( 54 ) TREATMENT 0F CELL PR0LIFERATIVE ( 30 ) F0reign Applicati0n Pri0rity Data DISORDERS WITH CHLOROTOXIN May 31 , 2002 ( US ) . 60384171 ( 76 ) 1nVent0rs : Vern0n L. AlVarez , Birmingham , AL Aug. 27 , 2002 ( US ) . 60406033 ( US ) ; MattheW A. G0nda , Birmingham , AL ( US ) Publicati0n Classiﬁcati0n C0rresp0ndence Address : ( 51 ) Int. Cl. MORGAN LEWIS & BOCKIUS LLP A61K 38 / 08 ( 2006.01 ) 1111 PENNSYLVANIA AVENUE NW C07K 7 / 06 ( 2006.01 ) WASHINGTON , DC 20004 ( US ) ( 52 ) U. S. Cl. . 514 / 16 ; 530 / 329 ; 530 / 328 ( 21 ) App1. N0. : 10 / 522 , s10 ( 57 ) . ABSTRACT . . . D1sc10sed1s a meth0d 0f treatmg ce11 pr011ferat1Ve d1s0rders , ( 22 ) PCT Fi1ed : Jun. 2 , 2003 such as cancer , With loW d0ses 0f ch10r0t0Xin and / 0r deriVa - . tiVes , ana10gs 0r fragments there0f , Which are eﬁectiVe t0 ( 86 ) PCT N0. : PCT / US03 / 17411 inhibit 0r arrest abn0rma1 ce11 gr0Wth. Patent Applicati0n Publicati0n Jul. 27 , 2006 Sheet 1 0f 12 US 2006 / 0166892 A1. Figure 1. . . ' Ds4 GBM. . o.5o o.4o o.3o. 0.20. . Average Absorbance ( 490 mm ) D S. . . 1bo. ooo 10. ooo 1. oQ0 - ‘o.1o0 o. o1o o.0o1 , o. ooo o. Uoo ‘ ' Ch10rotoxin ( 11M ) . . . . Patent Applicati0n Publicati0n Jul. 27 , 2006 Sheet 2 0f 12 US 2006 / 0166892 A1. Figure 2. . Optica1 Densi. . 1000 ' 10 - 0.1 0.001 0.00001 : ChlorotoXin ( nM ) . . . . Patent Applicati0n Publicati0n Jul. 27 , 2006 Sheet 3 0f 12 US 2006 / 0166892 A1. Figure 3. . P P P P P H N N w m m C m C 111. Averaége Absorbance ( 490 11111 ) . . lO0.00 l0.00 ' Chl0i‘€ ) 0t%xin ( ﬂND . 0.10 0.01. . . . Patent Applicati0n Publicati0n Jul. 27 , 2006 Sheet 4 0f 12 US 2006 / 0166892 A1. Figure 4. . D54 G1i0ma in Athymic Nude Mice. . 250130 ' 1. 20030 - . . . a h . §15000 h E C §1oo0o - g . + glé : rotoxm + mm - 7h ChlorutoxianCo 000 I . . . ; r , . . mm ( Dam. . . . Patent Applicati0n Publicati0n Jul. 27 , 2006 Sheet 5 0f 12 US 2006 / 0166892 A1. Figure 5. Kap1an - MeIar Surinval Chart of D§4MG Gﬂoblastoma IO Xenog raft : N Treatment with High and Low 00501 Chlorotoxin. ————————————————————————————. 100 Hm . - .— ; - Sal|ne Ll mmm Low. . . . . . . . . . . . . . . . . . E mClbc ngh. g 50 . ____________________________________ - - - - - - - - - - - - - - E Median Survival / / . iii SWys. “ - Clb : Iow = 35 days i. . . CItx high = 56 days. . . . . °. 11 1 M 111111 111 11.‘. 1“ .30. Days Post Tumor |mplantatIori. Patent Applicati0n Publicati0n Jul. 27 , 2006 Sheet 6 0f 12 US 2006 / 0166892 A1. Figure 6. . 500 I J. . . Cﬁlo rotoxln. + SalIne Alona ' n 400. 200 / / ) 11111 ' . A. 0 1o 00 ' 3 : 11 40 1 511 00 7 } ; aa 7 Days Post - lmplantation. . . . Percent of OrIgInaI Size. . . US 2006 / 0166892 A1. Patent Applicati0n Publicati0n Jul. 27 , 2006 Sheet 7 0f 12. Figure 7. RR mwAU euna LLLL. CSSSS QQQQQQ PPPPPPP mGGGGGGGG YYYYYYYYY CSSSSSSSSS . KKKKKKKKKKK. 25. MARKCDDCCGGKGRG. SSS. 20. Sequence. _ 5 10 15 Cltx MCMPCFTTDHQ. Pepﬁde 1 ' . GGGGGGGGGG RRRRRRRRRR GGGGGGGGGG KKKKKKKKKK GGGGGGGGGG GGGGGGGGGG. SSSSSSS. SSSSSSSSSS DDDDDDDDDD. DDDDDDDDDD SSSSSSSSSS KKKKKKKKKK RRRRRRRRRR AAAAAAAAAA MMMMMMMMMM QQQQQQQQQQ. HHHHHHHHHH DDDDDDDDD TTTTTfTT. Patent Applicati0n Publicati0n Jul. 27 , 2006 Sheet 8 0f 12 US 2006 / 0166892 A1. Figure 8. . Assay of Cltx Peptide Fragment Binding in PC3 Prostate Cancer Cells. . . . . . . % m - Avidin D Binding. . . . Cltx P eptide Fragment #. . . . Patent Applicati0n Publicati0n Jul. 27 , 2006 Sheet 9 0f 12. Figure 9. US 2006 / 0166892 A1. . % I - IRP - Avidin Bindin. . 600%. 500%. 400%. 300%. ) . 200%. 100%. 0% ' . Assay of Chlorotoxin Peptide Fragment Binding. in PC3 Prostate Cancer Cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . 111th 16 17 13 19 20 21 22 ' 23 24 25 an Peptide mgmente!. . . . . . . . . . . . . . . 26271510. . . Patent Applicati0n Publicati0n Jul. 27 , 2006 Sheet 10 0f 12 US 2006 / 0166892 A1. Figure 10. bC|lx mm wme : mae “evn - m._. mme ; 3e ~.~_4a - . ea. . . . . . . TDHQMARKS_ ' TAHQMARKS " - . . . . i ‘. ‘ﬂ TDAQMARKs 1. . ' ‘. ' - ‘ LL TDHAMARKS " ". 3 ' : : l¢. i‘_r : : - ' ar_i. ' . ' _. : - . A - G5 : MuLSL : w‘ ; m‘d. L¢_€ : S12hm { - , . - r"~. ' ~.5. TD HQAARKS : { 1 - ' : “1". ' : - ‘fT ; "‘ - " : "M N E : ‘~~M1 ll‘""!t" : : - " - ) - “ - ' ..\J : f‘ * ' 5 ' : " ; 1 ' { ‘ : "F ' ~ , ' $r ' * : ; “ ' i ' " r ~.."\" - } ~. : - " ' . ' - “" 7. - . u - . ; “ ' I ""‘ ; ; . ' - * ".“— ' ""."‘. ‘_ ' : ‘. . ~ " u I‘ A 4 - ‘ . TDHQMARKS “ . 1 e : - ‘" : ~r .~. - ‘ : .‘ r - ' \ ' |‘. ' . ' > ; ﬁ£mI TD H Q MMKS ii i - f. TI. : : ¢ - : i : u = : " : 5‘ : - . S ‘r . - ". TDHQMARKA " - ' =. . . . . . . . . . bCltx. . . . 0.000 0. D ' l0 - 0.020 0.030 0.040 ' 0.050 0.060 0.0?O 0.080 0.090 0.100. Patent Applicati0n Publicati0n Jul. 27 , 2006 Sheet 11 0f 12 US 2006 / 0166892 A1. Figure 11. . Peptide Binding in PC3 Human ' Pmstate Cance r Cells. . 21LQ : TIDQQMIKK 21S ' D ' I ' IDPQMSKK 21 : mHQmRKS Cltx‘. Negative Peptide. 0% se% 100% 150% 200% 250% 300% ' ' ' %HRP - AvD. . . . Patent Applicati0n Publicati0n Jul. 27 , 2006 Sheet 12 0f 12 US 2006 / 0166892 A1. Figure 12. . Effeci 01 Pep11de ' 21 on uptake of 3H - Thymidine in 00000 Ce||s . 10000.0 00000 eo00.0. 4000.0. 3H - Thymidine Updake ( CPM } . . 2000.0 , . . 0 ' 50 ‘ 100 ' 150 200 250 300 350 Concentration , nM ' . . . . US 2006 / 0166892 A1. TREATMENT 0F CELL PROLIFERATIVE DISORDERS WITH CHLOROTOXIN. RELATED APPLlCATIONS. [ 0001 ] This applicati0n claims the beneﬁt 0f U. S. Pr0Vi - si0nal Applicati0n 60 / 406 , 033 ( ﬁled Aug. 27 , 2002 ) and U. S. Pr0Visi0nal App1icati0n 60 / 384 , 171 ( ﬁ1ed May 31 , 2002 ) b0th 0f Which are hereby inc0rp0rated by reference in their entirety. FlELD OF THE lNVENTlON. [ 0002 ] 0f cell physi0l0gy and 0nc0l0gy. M0re speciﬁcally , the present inVenti0n re1ates t0 a n0Ve1 meth0d 0f treating cel1 pr0liferatiVe dis0rders , such as cancers , with d0ses 0f chl0 - r0t0Xin and / 0r deriVatiVes there0f Which are eﬁfectiVe t0 inhibit 0r arrest abn0rma1 ce1l gr0Wth. The present inVenti0n relates general1y t0 the ﬁelds. BACKGROUND OF THE lNVENTlON. [ 0003 ] Tum0rs that 0riginate in brain tissue are kn0Wn as primary brain tum0rs as 0pp0sed t0 sec0ndary brain tum0rs that deVe10p When cancer metastasizes fr0m 0ther parts 0f the b0dy t0 the brain. Primary brain tum0rs are c1assiﬁed by the type 0f tissue in Which they begin. The m0st c0mm0n brain tum0rs are gli0mas , Which begin in the glial ( supp0rtiVe ) tissue. Astr0cyt0mas are a type 0f g1i0ma that arise fr0m sma11 , star - shaped ce11s ca11ed astr0cytes. They may gr0W anyWhere 111 the brain 0r spinal c0rd but m0st 0ften arise in the cerebrum in adults and the brain stem , the cerebrum , and the cerebel1um in children. A grade III astr0cyt0ma is s0metimes ca11ed anap1astic astr0cyt0ma Whi1e a grade lV astr0cyt0ma is usua11y ca11ed g1i0b1ast0ma mu1tif0rme. Brain stem gli0mas 0ccur in the loWest , stemlike part 0f the brain. Tum0rs in this area generally cann0t be rem0Ved. M0st brain stem gli0mas are high - grade astr0cyt0mas. Ependym0mas are a type 0f g1i0ma that usua11y deVe10p in the 11ning 0f the Ventric1es and may a1s0 0ccur in the spina1 c0rd. Alth0ugh these tum0rs can deVel0p at any age , they are m0st c0mm0n in childh00d and ad0lescence. Olig0dendr0 - g1i0mas arise in the cells that pr0duce myelin , the fatty c0Vering that pr0tects nerVes. These rare tum0rs usua11y arise in the cerebrum , gr0W sl0W1y , usua11y d0 n0t spread int0 surr0unding brain tissue and 0ccur m0st 0ften in middle - aged adults but haVe been f0und 111 pe0ple 0f all ages. [ 0004 ] There are 0ther types 0f brain tum0rs that d0 n0t 0riginate in glial tissue. Medull0blast0mas Were 0nce th0ught t0 deVe10p fr0m g1ia1 ce11s. HOWeVer , recent research suggests that these tum0rs deVe10p fr0m primitiVe ( deVel0ping ) nerVe cells that n0rmally d0 n0t remain in the b0dy after birth. F0r this reas0n , medull0blast0mas are sOmetimes cal1ed primitiVe neur0ect0dermal tum0rs. M0st medu110b1ast0mas arise in the cerebe11um , h0WeVer , they may 0ccur in 0ther areas as Well Meningi0mas gr0W fr0m the meninges and are usually benign. Because these tum0rs gr0W Very sl0le , the brain may be able t0 adjust t0 their presence and theref0re these tum0rs 0ften groW quite large bef0re they cause sympt0ms. SchWann0mas are benign tum0rs that begin in SchWann cel1s , Which pr0duce the mye1in that pr0tects the ac0ustic nerVe. Ac0ustic neur0mas are a type 0f schWann0ma and 0ccur mainly in adults. Crani0pharyngi0mas deVel0p in the regi0n 0f the pituitary. Jul 27 , 2006. gland near the hyp0thalamus and are usually benign , h0W - eVer , they are s0metimes c0nsidered malignant because they can press 0n 0r damage the hyp0thalamus and affect Vital functi0ns. Ge1m cell tum0rs arise fr0m primitiVe ( deVel0p - ing ) seX cel1s 0r ge1m ce11s. The m0st frequent type 0f germ cell tum0r in the brain is the germin0ma. Pineal regi0n tum0rs 0ccur in 0r ar0und the pineal g1and , a tiny 0rgan near the center 0f the brain. The tum0r can be sl0W gr0Wing ( pine0cyt0ma ) 0r fast gr0Wing ( pine0b1ast0ma ) . The pinea1 regi0n is Very diﬁicu1t t0 reach , and these tum0rs 0ften cann0t be rem0Ved. [ 0005 ] PrimitiVe neur0ect0dermal tum0rs are f0und b0th in the central and peripheral nerV0us systems. PrimitiVe neur0ect0de1ma1 tum0rs f0und 0nly in the peripheral ner - V0us system are referred t0 as periphera1 primitiVe neur0 - ect0dermal tum0rs. PrimitiVe neur0ect0dermal tum0rs manifest preferentially in children and haVe capacity f0r deVe10ping mm a Variety 0f neur0na1 , astr0cytic , ependyma1 , muscu1ar and me1an0tic 11nes. The c0nceptua1 basis 0f gr0uping these tum0rs t0gether is based up0n sharing 00m - m0n pr0genit0r cells as Well as sharing similar ne0plastic transf0rmati0ns leading t0 tum0rs 0f similar m0rph0l0gical features and bi010gica1 behaVi0r. HOWeVer , there remains 00ntr0Versy in placing all primitiVe neur0ect0derma1 tum0rs mm the same categ0ries. [ 0006 ] Supratent0rial primitiVe neur0ect0dermal tum0rs include cerebral medull0blast0mas , cerebral neur0blast0 - mas , ependym0b1ast0ma and 0ther primitiVe neur0ect0der - ma1tum0rs , such as pine0blast0mas. Peripheral neur0blastic tum0rs 0f the adrenal gland ( medulla ) and sympathetic nerV0us system are the m0st c0mm0n type 0f childh00d tum0r 0utside 0f the centra1 nerV0us system. Primary sites f0r these primitiVe neur0ect0derma1 tum0rs are in the adrena1s , abd0mina1 , th0racic , cerVica1 and pe1Vic sympathetic ganglia but include 0ther primary sites as 0rbit , kidney , lung , skin , 0Vary , spermatic c0rd , and urinary bladder. Speciﬁc names 0f these re1ated tum0rs are phe0chr0 - m0cyt0mas , paraganghoma , neur0b1ast0mas , gang1i0neur0 - mas , gangli0neur0b1ast0mas , neur0ﬁbr0mas , schWann0mas , and malignant peripheral nerVe sheath tum0rs. These all share c0mm0n 0rigin in the neural crest. Medull0blast0mas are members 0f the primitiVe neur0ect0dermal tum0rs that are described as high1y ma1ignant embry0na1 tum0rs 0f the centra1 nerV0us system f0und in the cerebellum. [ 0007 ] Currently , surgery is the treatment 0f ch0ice f0r tum0rs 0f the central nerV0us system. Surgery pr0Vides a deﬁnite diagn0sis , relieVes the mass bulkiness 0f the tum0r and eXtends surViVa1 0f the patient. The 0n1y p0st - surgery adjuVant treatment Which is kn0Wn t0 W0rk elfectiVe1y 0n central nerV0us system tum0rs is radiati0n , and it can pr0l0ng surViVal. Radiati0n treatment , h0WeVer , has many undesirable side effects. It can damage the n0rmal tissue 0f the patient , inc1uding the neur0na1 tissue. Radiati0n a1s0 can cause seVere side eifects ( e. g. , nausea , V0miting , hair 10ss ) . [ 0008 ] The 0ther 00mm0n p0st - surgery adjuVant cancer treatment , chem0therapy , is relatiVely ineﬁectiVe against neur0ect0dermal tum0rs. F0r eXample , chem0therapy against neur0ect0derma1 tum0rs with nitr0s0urea agents is n0t curatiVe. Many 0ther cancer treating agents haVe been studied and tested , but genera1ly they haVe a minimal eﬁect 0n eXtending surViVal because many agents d0 n0t cr0ss the bl00d - brain barrier. ln VieW 0f these limited treatment. US 2006 / 0166892 A1. 0pti0ns , the current pr0gn0sis f0r patients diagn0sed With neur0ect0derma1 tum0rs is n0t faV0rable. The median surViVal term f0r patients diagn0sed With malignant astr0cyt0 - mas haVing surgery and n0 adjuVant treatment is ab0ut f0urteen Weeks. Radiati0n therapy after surgery eXtends the median t0 ab0ut thirty - six Weeks. The current tW0 year surViVa1 rate f0r all f0rms 0f treatment is 1ess than ten percent. [ 0009 ] Other types 0f tum0rs are a1s0 diﬁicu1t t0 00mbat by kn0Wn cancer treatments. Lung cancer ki1ls m0re Americans annually than the next f0ur m0 st frequently diagn0sed ne0plasms c0mbined ( Greenlee et al. ( 2001 ) CA Cancer J. C1in. 51 , 15 - 36 ) . Appr0Ximate1y eighty percent 0f primary 1ung tum0rs are 0f the n0n - smal1 cell Variety , Which includes squam0us ce1l and large cel1 carcin0mas , as Well as aden0 - carcin0mas. Single - m0dality therapy is c0nsidered appr0 - priate f0r m0st cases 0f early and late stage n0n - small cell 1ung cancer. Ear1y stage tum0rs are p0tentia11y curab1e With surgery , chem0therapy , 0r radi0therapy , and 1ate stage patients usually receiVe chem0therapy 0r best supp0rtiVe care. lntermediate stage 0r lOcally adVanced n0n - small cell lung cancer , Which c0mprises tWenty - ﬁVe t0 thirty - ﬁVe percent 0f a11 cases , is m0re typica11y treated With mu1ti - m0dality therapy. [ 0010 ] Breast cancer a1s0 presents treatment diﬁicu1ties using kn0Wn agents. The incidence 0f breast cancer in the United States has been rising at a rate 0f ab0ut tW0 percent per year since 1980 , and the American Cancer SOciety estimated that 192 , 000 cases 0f inVasiVe breast cancer Were diagn0sed in 2001. Breast cancer is usua11y treated With surgery , radi0therapy , chem0therapy , h01m0ne therapy 0r c0mbinati0ns 0f the Vari0us meth0ds. A maj 0r reas0n f0r the failure 0f cancer chem0therapy in breast cancer is the deVel0pment 0f resistance t0 the cyt0t0Xic drugs. C0mbina - ti0n therapy using drugs With dilferent mechanisms 0f acti0n is an accepted meth0d 0f treatment Which preVents deVe1 - 0pment 0f resistance by the treated tum0r. Anti - angi0genic agents are particularly useful in c0mbinati0n therapy because they are n0t likely t0 cause resistance deVel0pment since they d0 n0t act 0n the tum0r , but 0n n0rma1 h0st tissue. [ 0011 ] Chl0r0t0Xin is a thirty - six amin0 acid pr0tein natural1y deriVed fr0m / e1 ' urus quinquestriatus sc0rpi0n Ven0m ( DeBin et a1. ( 1993 ) Am. J. Physi01. 264 : C361 - 369 ) . C0mp0siti0ns ( see U. S. Pat. N0s. 5 , 905 , 027 and 6 , 429 , 187 each 0f Which is hereby inc0rp0rated by reference in their entirety ) and meth0ds ( see U. S. Pat. N0s. 6 , 028 , 174 and 6 , 3 l 9 , 89l each 0f Which is hereby inc0rp0rated by reference in their entirety ) f0r diagn0sing and treating neur0ect0dermal tum0rs ( e. g. , g1i0mas and meningi0mas ) haVe been deVel0ped based 0n the ability 0f chl0r0t0xin t0 bind t0 tum0r cells 0f neur0ect0dermal 0rigin ( S0r0ceanu et al. ( 1998 ) Cancer Res. 58 , 487l - 4879 ; Ullrich et al. ( l996 ) Neur0rep0rt 7 , 1020 - 1024 ; U11rich et a1. ( 1996 ) Am. J. Physi0l. 270 , C1511 - C1521 ) . Diagn0sis 0f neur0ect0derma1 tum0rs is acc0mplished by identiﬁcati0n 0f labeled chl0r0 - t0Xin b0und t0 tum0r cells While treatment 0f neur0ect0dermal tum0rs is acc0mplished by targeting tum0rs With cyt0 - t0Xic agents 11nked t0 chl0r0t0Xin. The present inVenti0n eXpands this area 0f therapeutics by pr0Viding a meth0d f0r treating ce11 pr01iferatiVe diseases , such as cancer , using ch10r0t0Xin and / 0r deriVatiVes there0f. The present inVen - ti0n als0 includes neW t0xin - deriVed therapeutic m0lecules. Jul 27 , 2006. SUMMARY OF THE INVENTION. [ 0012 ] The present inVent0rs haVe f0und that 10W d0ses 0f ch10r0t0Xin and / 0r deriVatiVes there0f , 0n the 0rder 0f ab0ut lO - 1 , 000 times loWer than preVi0usly discl0sed f0r the targeted treatment 0f gli0ma and meningi0ma and can inhibit 0r arrest the gr0Wth 0f tum0r cells When said l0W d0ses 0f ch10r0t0Xin and / 0r deriVatiVes there0f , 0n the 0rder 0f 1ess than 2.0 mg / kg b0dy Weight 0f a subject are administered 0n their 0Wn. The present inVent0rs haVe further f0und that these d0ses 0f chl0r0t0Xin and / 0r deriVatiVes there0f can elfectiVe1y inhibit 0ther types 0f cancer ce11s inc1uding , but n0t limited t0 , pr0state cancer , breast cancer , and n0n - smal1 ce11 1ung carcin0ma. [ 0013 ] The inVenti0n enc0mpasses an is0lated p01ypeptide 00mprising a subunit 0f ch10r0t0Xin 0r a related sc0rpi0n t0Xin , Wherein the p0lypeptide speciﬁcally binds t0 a cancer cell. ln sOme emb0diments the is0lated p0lypeptide c0m - prises an amin0 acid sequence se1ected fr0m the gr0up 00nsisting 0f SEQ lD NO : 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 and 14. The inVenti0n inc1udes t0Xin p0lypeptides c0mprising the amin0 acid sequence TTX1X2X3MX4X5K ( SEQ lD NO : l3 ) , Wherein X1 is an acidic amin0 acid selected fr0m the gr0up c0nsisting 0f aspartic acid and g1utamic acid ; X2 is an amin0 acid selected fr0m the gr0up c0nsisting 0f a1anine , arginine , asparagine , aspartic acid , cysteine , glutamine , glutamic acid , glycine , histidine , is0leucine , leucine , lysine , pr0line , methi0nine , pheny1alanine , serine , thre0nine , tryp - t0phan , tyr0sine and Va1ine ; X3 is an amide amin0 acid selected fr0m the gr0up c0nsisting 0f asparagine and glutamine ; X4 is an amin0 acid selected fr0m the gr0up c0nsisting 0f serine , thre0nine and alanine ; and X5 is a basic amin0 acid se1ected fr0m the gr0up c0nsisting 0f histine , 1ysine and arginine. ln 0ne emb0diment , the is01ated p01ypeptide 00mprises the amin0 acid sequence 0f SEQ lD NO : 14 ( TTDHQMARK ) , SEQ lD NO : 94 ( TTDQQMTKK ) 0r SEQ ID NO : 95 ( TTDPQMSKK ) . [ 0014 ] The chl0r0t0Xin and chl0r0t0Xin deriVatiVes 0f the inVenti0n bind t0 cancer ce11s se1ected fr0m the gr0up 00nsisting 0f 1ung cancer , b0ne cancer , 11Ver cancer , pancreatic cancer , skin cancer , cancer 0f the head 0r neck , cuta - ne0us 0r intra0cular melan0ma , uterine cancer , 0Varian cancer , rectal cancer , cancer 0f the anal regi0n , st0mach cancer , c010n cancer , breast cancer , uterine cancer , carci - n0ma 0f the fa1l0pian tubes , carcin0ma 0f the end0metrium , carcin0ma 0f the cerVix , carcin0ma 0f the Vagina , carcin0ma 0f the VulVa , H0dgkins Disease , cancer 0f the es0phagus , cancer 0f the small intestine , cancer 0f the end0crine system , cancer 0f the thyr0id g1and , cancer 0f the parathyr0id g1and , cancer 0f the adrena1 gland , sarc0ma 0f s0ft tissue , cancer 0f the urethra , cancer 0f the penis , pr0state cancer , chr0nic 0r acute leukemia , lymph0cytic lymph0mas , cancer 0f the bladder , cancer 0f the kidney 0r ureter , renal ce1l carcin0ma , carcin0ma 0f the rena1 pe1Vis , ne0p1asms 0f the centra1 nerV0us system ( CNS ) , neur0ect0derma1 cancer , spinal aXis tum0rs , gli0ma , meningi0ma and pituitary aden0ma. [ 0015 ] tide c0mprising a subunit 0f chl0r0t0Xin 0r a related sc0r - pi0n t0Xin as described ab0Ve , 11nked t0 a sec0nd p0lypeptide. ln s0me emb0diments , the sec0nd p01ypeptide c0mprises a cancer ce11 - binding d0main Which binds spe - ciﬁcally 0f an epit0pe eXpressed 0nly by a cancer cell. Examples 0f a cancer cell - binding d0main include , but are. The inVenti0n als0 enc0mpasses a fusi0n p0lypep - . US 2006 / 0166892 A1. n0t limited t0 , an antib0dy 0r fragment there0f. In 0ther emb0diments , the sec0nd p0lypeptide c0mprises a stabilizati0n d0main Which preVent degradati0n 0f the fusi0n p01ypeptide. EXamp1es 0f a stabi1izati0n d0main inc1ude , but are n0t limited t0 , human serum albumin and transferrin. The stabilizati0n d0main can als0 include multimers 0f chl0r0 - t0Xin 0r a ch10r0t0Xin deriVatiVe , 0r chemical m0ieties such as PEG , p0ly - lysine , carb0hydrates , fatty acids , and lipids. [ 0016 ] ln s0me emb0diments 0f the inVenti0n , chl0r0t0Xin 0r a ch10r0t0Xin deriVatiVe is linked t0 a cyt0t0Xic agent. EXamples 0f cyt0xic agents include , but are n0t limited t0 , gel0nin , ricin , sap0nin , pseud0n0mas ex0t0Xin , p0keWeed antiViral pr0tein , diphtheria t0Xin and c0mplement pr0teins. ln 0ther emb0diments , ch10r0t0xin 0r a ch10r0t0Xin deriVatiVe is 1abeled. ln a preferred emb0diment the 1abe1 is radi0actiVe. The inVenti0n includes c0mp0siti0ns c0mprising any 0f the chl0r0t0xin 0r chl0r0t0Xin deriVatiVes 0f the inVenti0n as described ab0Ve. [ 0017 ] The inVenti0n further includes a meth0d 0f treating a disease characterized by abn0rmal cel1 pr0liferati0n in a mammal c0mprising administering the c0mp0siti0n c0m - prising the any 0f the chl0r0t0Xin deriVatiVes 0f the inVen - ti0n as described ab0Ve. The inVenti0n a1s0 enc0mpasses a meth0d 0f treating a disease in a mamma1 characterized by abn0rmal cell pr0liferati0n c0mpri sing administering a c0m - p0siti0n c0nsisting essentially 0f chl0r0t0xin 0r a related sc0rpi0n t0Xin. ln a preferred emb0diment , the c0mp0siti0n is suitab1e f0r use in humans and the mamma1 is a human. ln s0me emb0diments , the disease is cancer. Types 0f cancer include , but are n0t limited t0 , lung cancer , b0ne cancer , liVer cancer , pancreatic cancer , skin cancer , cancer 0f the head 0r neck , cutane0us 0r intra0cu1ar me1an0ma , uterine cancer , 0Varian cancer , recta1 cancer , cancer 0f the ana1 regi0n , st0mach cancer , c010n cancer , breast cancer , uterine cancer , carcin0ma 0f the fall0pian tubes , carcin0ma 0f the end0metrium , carcin0ma 0f the cerVix , carcin0ma 0f the Vagina , carcin0ma 0f the Vu1Va , H0dgkins Disease , cancer 0f the es0phagus , cancer 0f the sma11 intestine , cancer 0f the end0crine system , cancer 0f the thyr0id g1and , cancer 0f the parathyr0id gland , cancer 0f the adrenal gland , sarc0ma 0f sOft tissue , cancer 0f the urethra , cancer 0f the penis , pr0 state cancer , chr0nic 0r acute leukemia , 1ymph0cytic lymph0mas , cancer 0f the b1adder , cancer 0f the kidney 0r ureter , rena1 ce11 carcin0ma , carcin0ma 0f the rena1 pelVis , ne0plasms 0f the central nerV0us system ( CNS ) , neur0ect0dermal cancer , spinal aXis turn0rs , gli0ma , meningi0ma and pituitary aden0ma. [ 0018 ] The meth0ds 0f the inVenti0n inc1ude administra - ti0n 0f ch10r0t0xin 0r a chl0r0t0Xin deriVatiVe in an am0unt less than ab0ut 0.1 mg / kg b0dy Weight , preferably less than ab0ut 0.05 mg / kg b0dy Weight , eVen m0re preferably in a range 0f ab0ut 0.01 ug / kg b0dy Weight t0 ab0ut 0.1 mg / kg b0dy Weight , yet eVen m0re preferab1y ab0ut 0.1 ug / kg b0dy Weight t0 ab0ut 0.1 mg / kg b0dy Weight , inc1uding ab0ut 0.1 ug / kg b0dy Weight t0 ab0ut 0.05 mg / kg b0dy Weight , and m0st preferably in a range 0f ab0ut 0.1 ug / kg b0dy Weight t0 ab0ut 2.0 mg / kg b0dy Weight. [ 0019 ] The inVenti0n further inc1udes is0lated nuc1eic acid m0lecu1e enc0ding the ch10r0t0xin p0lypeptide and chl0r0 - t0Xin deriVatiVe p01ypeptides 0f the inVenti0n. ln s0me emb0diments , the nucleic acid m0lecule is 0perably linked t0 0ne 0r m0re eXpressi0n c0ntr0l elements. The inVenti0n. Jul 27 , 2006. includes Vect0rs 00mprising these nucleic acid m0lecules and h0st cells c0ntaining these Vect0rs. ln some emb0diments , the h0st cell is a pr0kary0tic 0r eukary0tic h0st cells. The inVenti0n enc0mpasses a meth0d f0r pr0ducing a p01ypeptide 00mprising cu1turing these h0st ce1ls under c0nditi0ns in Which the p0lypeptide enc0ded by said nucleic acid m0lecule is eXpressed. BRlEF DESCRlPTlON OF THE DRAWlNGS. [ 0020 ] FIG. 1 depicts a cyt0t0xicity assay in Which l0W 00ncentrati0ns 0f ch10r0t0Xin are sh0Wn t0 inhibit the gr0Wth and pr0liferati0n 0f g1i0blast0ma cel1s. [ 0021 ] FIG. 2 depicts the elfect 0f f0ur day incubati0n and Wash - 0ut 0n the abi1ity 0f ch10r0t0xin t0 inhibit abn0rma1 cell gr0Wth. [ 0022 ] FIG. 3 depicts a cyt0t0xicity assay in Which lOW c0ncentrati0ns 0f chl0r0t0Xin are sh0Wn t0 inhibit the gr0Wth and pr0liferati0n 0f pr0state cancer cells. [ 0023 ] FIG. 4 depicts an in ViV0 assay 0f the ability 0f ch10r0t0Xin t0 inhibit the gr0Wth 0f gli0blast0ma tum0r cells in athymic nude mice. [ 0024 ] FIG. 5 depicts an in ViV0 assay 0f the ability 0f ch10r0t0Xin t0 enhance surViVa1 0f athymic nude mice With intracranial g1i0blast0ma tum0rs. Cessati0n 0f intraVen0us treatment indicated by arr0W. [ 0025 ] FIG. 6 depicts an in ViV0 assay 0f the abi1ity 0f ch10r0t0Xin t0 inhibit gr0Wth 0f gli0blast0ma tum0rs in the flanks 0f athymic nude mice. [ 0026 ] FIG. 7 depicts a series 0f 0Verlapping lO - mer peptides deriVed fr0m chl0r0t0Xin. Cysteine residues 0f SEQ lD NO : 1 are rep1aced in the 10 - mers With serine t0 preVent cr0ss - 1inking 0f peptides. [ 0027 ] FIG. 8 depicts binding 0f ch10r0t0Xin and 10 - mer peptides 1 - 15. [ 0028 ] FIG. 9 depicts binding 0f ch10r0t0Xin and 10 - mer peptides 16 - 27 , 1 , 5 and 10. [ 0029 ] 00re 9 - mer , and each a1anine - substituted 9 - mer peptide t0 b0th U251 and PC3 ce1ls. [ 003 0 ] FIG. 11 depicts binding 0f sh0rt sc0rpi0n t0Xins in PC3 human pr0state cancer cel1s. [ 0031 ] FIG. 12 depicts the elfect 0f peptide 21 0n the pr0liferati0n 0f D54MG ce11s Was studied by adding increasing d0ses 0f peptide 21 t0 the cells and then measuring the uptake 0f 3H - thymidine. FIG. 10 depicts binding 0f peptide 21 , the natiVe. DETAlLED DESCRlPTlON OF THE lNVENTlON. [ 0032 ] lt has been determined that 10W d0ses 0f ch10r0 - t0Xin , 0n the 0rder 0f ab0ut 10 - 1 , 000 times loWer than preVi0usly discl0sed f0r the treatment 0f gli0ma an menin - gi0ma , haVe a cyt0static e1fect 0n actiVely pr0liferating cells and can inhibit 0r arrest the gr0Wth 0f tum0r cells With0ut the additi0n 0f 0ther eX0gen0us therapeutic agents f0r the treatment 0f ce11 pr0liferatiVe dis0rders , including , but n0t 11mited t0 , g1i0mas , meningi0mas , pr0state cancer , breast cancer and n0n - small cell lung carcin0mas. Furtherm0re , p0lypeptide deriVatiVes 0f chl0r0t0Xin c0ntaining 0ne 0r. US 2006 / 0166892 A1. m0re 0f the regi0ns discl0sed herein can be used f0r the treatment 0f cell pr0liferatiVe dis0rders in a manner similar t0 natiVe chl0r0t0xin. [ 0033 ] lnhibiti0n 0r arrest 0f cel1 pr0liferati0n ass0ciated With a disease , such as cancer , can serVe t0 enhance natura1 defenses Within the subject. F0r examp1e , arresting 0r inhibiting the gr0Wth 0f cancer ce11s enhances the ability 0f the immune system t0 m0unt a m0re effectiVe resp0nse t0 the cancer. Further , arresting 0r inhibiting cell pr0liferati0n can sl0W angi0genesis , starVing the tum0r 0f nutrients and further enhances the ki1ling 0r eliminati0n 0f the tum0r. Ch10r0t0xin and DeriVatiVe P0lypeptides. [ 0034 ] This inVenti0n includes a pharmaceutical c0mp0 - siti0n f0r the treatment 0f abn0rma1 ce11 gr0Wth 0r f0r a disease characterized by cel1 pr0liferati0n in a mamma1 , including a human , c0mprising , c0nsisting essentia11y 0f , 0r c0nsisting 0f an am0unt 0f chl0r0t0xin and / 0r deriVatiVes there0f that is eﬁectiVe in inhibiting abn0rma1 cel1 gr0Wth and a pharmaceutica11y acceptab1e canier. As used herein , the terms “abn01ma1 ce1l gr0Wth” and “disease characterized by cell pr0liferati0n” unless 0therWise indicated , refer t0 cell gr0Wth that is independent 0f n0rmal regulat0ry mechanisms ( e. g. , lOSS 0f c0ntact inhibiti0n ) . This inc1udes the abn0rmal gr0Wth and / 0r pr01iferati0n 0f ce11s in b0th benign and malignant cel1s 0f ne0p1astic diseases. lnhibiti0n 0f abn0r - mal cell gr0Wth can 0ccur by a Variety 0f mechanisms including , but n0t limited t0 , cell death , ap0pt0sis , arrest 0f mit0sis , inhibiti0n 0f ce11 diVisi0n , transcripti0n , trans1ati0n , transducti0n , etc. [ 0035 ] As used herein , an “effectiVe am0unt” 0f chl0r0 - t0xin is an am0unt Which exerts an e1fect 0n cells exhibiting abn0rma1 gr0Wth , such as cancer ce11s. As used herein , c0mp0siti0ns c0mprising , treatment With 0r administrati0n 0f “chl0r0t0xin” includes t0 the same degree treatment With chl0r0t0xin anal0gues , deriVatiVes , fragments , Variants , related peptides and mimetics discl0sed herein. [ 0036 ] ln 0ne emb0diment 0f the c0mp0siti0n and meth - 0ds 0f the inVenti0n , the abn0rmal cell gr0Wth is cancer. As used herein , the term “cancer” unless 0therWise indicated , refers t0 diseases that are characterized by unc0ntr011ed , abn0rma1 ce11 gr0Wth and / 0r pr01iferati0n. Types 0f cancer Where the c0mp0siti0ns are useful include , but are n0t limited t0 , pr0state cancer , breast cancer , lung cancer , n0n - small cell lung carcin0ma , b0ne cancer , liVer cancer , pancreatic cancer , skin cancer , cancer 0f the head 0r neck , cutane0us 0r intra0cu1ar me1an0ma , uterine cancer , 0Varian cancer , recta1 cancer , cancer 0f the ana1 regi0n , st0mach cancer , c0l0n cancer , uterine cancer , carcin0ma 0f the fallopian tubes , carcin0ma 0f the end0metrium , carcin0ma 0f the cerVix , carcin0ma 0f the Vagina , carcin0ma 0f the Vu1Va , H0dgkins Disease , cancer 0f the es0phagus , cancer 0f the small intestine , cancer 0f the end0crine system , cancer 0f the thyr0id gland , cancer 0f the parathyr0id gland , cancer 0f the adrenal gland , sarc0ma 0f soft tissue , cancer 0f the urethra , cancer 0f the penis , chr0nic 0r acute leukemia , lymph0cytic 1ymph0mas , cancer 0f the b1adder , cancer 0f the kidney 0r ureter , renal cel1 carcin0ma , carcin0ma 0f the rena1 pe1Vis , ne0plasms 0f the central nerV0us system ( CNS ) , neur0ec - t0dermal cancers , spinal axis tum0rs , gli0ma , meningi0ma , pituitary aden0ma , 0r a c0mbinati0n 0f 0ne 0r m0re 0f the f0reg0ing cancers. [ 0037 ] ln an0ther emb0diment 0f the c0mp0siti0ns and meth0ds 0f the inVenti0n , the abn0rmal cell gr0Wth is a. Jul 27 , 2006. benign pr0liferatiVe disease , including , but n0t limited t0 , benign pr0static hyperplasia , hypertr0phy 0r restin0sis. [ 0038 ] As discussed ab0Ve , the inVenti0n includes c0m - p0siti0ns and meth0ds f0r the treatment 0f abn0rma1 cell gr0Wth in a mammal , including a human , Which c0mprises , 00nsists 0f , 0r 00nsists essentia1ly 0f an elfectiVe am0unt 0f a chl0r0t0xin , in c0mbinati0n With a pharmaceutical1y acceptab1e carrier. [ 0039 ] As used herein , the term “ch10r0t0xin” unless 0therWise described , refers t0 the fu1l - length , thirty - six amin0 acid p0lypeptide naturally deriVed fr0m Leiums quinquestriatus sc0rpi0n Ven0m ( DeBin et al. ( 1993 ) Am. S. Physi01. 264 , C361 - 369 ) Which c0mprises the amin0 acid sequence 0f natiVe ch10r0t0xin as set f0rth in SEQ lD NO : 1. The term “chl0r0t0xin” inc1udes p01ypeptides 00mprising SEQ lD NO : 1 Which haVe been synthetically 0r rec0mbinantly pr0duced , such as th0se discl0sed in U. S. Pat. N0. 6 , 319 , 891 , Which is herein inc0rp0rated by reference in its entirety. [ 0040 ] As used herein , the term “ch10r0t0xin subunit” 0r “subunit 0f ch10r0t0xin” refers t0 a peptide c0mprising less than thirty - six c0ntigu0us amin0 acids 0f chl0r0t0xin and Which is capable 0f speciﬁcally binding t0 cancer cells. [ 0041 ] As used herein , the term “chl0r0t0xin deriVatiVe” refers t0 deriVatiVes , anal0gs , Variants , p0lypeptide fragments and mimetics 0f chl0r0t0xin and related peptides Which retain the same actiVity as ch10r0t0xin , such as binding speciﬁca11y binding t0 a cancer ce11 When c0mpared t0 a n0rmal cell , can als0 be used f0r practicing the meth0ds 0f the inVenti0n. Examples 0f deriVatiVes include , but are n0t limited t0 , peptide Variants 0f chl0r0t0xin , peptide fragments 0f ch10r0t0xin , f0r examp1e , fragments c0mprising 0r c0nsisting 0f c0ntigu0us 10 - mer peptides 0f SEQ lD NO : 1 , 2 , 3 , 4 , 5 , 6 0r 7 0r c0mprising ab0ut residues 10 - 18 0r 21 - 30 0f SEQ lD NO : l , c0re binding sequences , and peptide mimetics. [ 0042 ] Chl0r0t0xin and peptide deriVatiVes there0f can be prepared using standard sOlid phase ( 0r s0luti0n phase ) peptide synthesis meth0ds , as is kn0Wn in the art. ln addi - ti0n , the nuc1eic acids enc0ding these peptides may be synthesized using c0mmercially aVailab1e 01ig0nuc1e0tide synthesis instrumentati0n and pr0duced rec0mbinantly using standard rec0mbinant pr0ducti0n systems. The pr0 - ducti0n using s01id phase peptide synthesis is necessitated if n0n - gene - enc0ded amin0 acids are t0 be inc1uded. The term “chl0r0t0xin deriVatiVe” as used herein is syn0nym0us With “Variant” als0 includes m0diﬁcati0ns t0 the chl0r0t0xin sequence by 0ne 0r m0re deleti0ns 0f up t0 lO ( e. g. , 1 t0 7 0r 1 t0 5 amin0 acids ; inserti0ns 0f a t0tal 0f up t0 10 ( e. g. , 1 t0 5 ) amin0 acids interna1ly Within the amin0 acid sequence 0f ch10r0t0xin ; 0r 0f up t0 a t0ta1 0f 100 amin0 acids at either terminus 0f the chl0r0t0xin sequence ; 0r c0nserVatiVe substituti0ns 0f a t0tal 0f up t0 15 ( e. g. , 1 t0 5 ) amin0 acids. [ 0043 ] c0mprising a c0nserVatiVe 0r n0n - c0nserVatiVe substituti0n 0f at least 0ne amin0 acid residue When the deriVatiVe sequence and the chl0r0t0xin sequence are maximal1y aligned. The substituti0n may be 0ne Which enhances at 1east 0ne pr0perty 0r functi0n 0f chl0r0t0xin , inhibits at least 0ne pr0perty 0r functi0n 0f chl0r0t0xin , 0r is neutral t0 at least. DeriVatiVes 0f chl0r0t0xin include p0lypeptides. US 2006 / 0166892 A1. one pr0perty or function of chl0r0t0xin. As used herein , a “pr0perty 0r function” 0f chlorot0xin includes , but is n0t 11mited t0 , at least 0ne selected from the group consisting of the abi1ity to arrest abnormal ce11 grthh , cause paralysis of a subject , speciﬁc binding t0 a benign 0r ma1ignant cancer ce1l When c0mpared t0 a non - cancer cel1 ( i. e. , n0rmal ) , and killing 0f a benign 0r malignant cancer cell. In terms 0f the present disclosure , the cancer cell may be in ViVo , ex ViVo , in Vitro , a primary isolate from a subject , a cu1tured ce1l or a cel1 11ne. [ 0044 ] DeriVatiVes of ch1orotoxin further include polypeptides comprising the amino acid sequence KGRGKSY ( SEQ lD NO : 8 ) , corresp0nding t0 amin0 acid residues 23 - 29 0f SEQ lD NO : 1. DeriVatiVes 0f ch10r0toxin als0 include p01ypeptides comprising the amino acid sequence TTXlX2X3MX4X5K ( SEQ lD NO : 13 ) corresponding to amino acid residues 7 - 15 0f SEQ lD NO : 1 , Wherein X1 is an acidic amin0 acid selected fr0m the gr0up c0nsisting 0f aspartic acid and glutamic acid ; X2 is an amino acid selected fr0m the gr0up consisting of a1anine , arginine , asparagine , aspartic acid , cysteine , g1utamine , g1utamic acid , glycine , histidine , isoleucine , leucine , lysine , pr0line , methionine , phenylalanine , serine , thre0nine , trypt0phan , tyr0sine and Valine ; X3 is an amide amino acid selected fr0m the group c0nsisting 0f asparagine and g1utamine ; X4 is an any amino acid but in a preferred embodiment is se1ected from the group consisting of serine , threonine and alanine ; and X5 is a basic amino acid selected from the group c0nsisting of histine , 1ysine and arginine. ln 0ne emb0diment , X1 is aspartic acid , X2 is histidine 0r pr01ine , X3 is g1utamine , X4 is a1anine and X5 is arginine or lysine. Jul 27 , 2006. [ 0045 ] Peptide Variants 0f chlor0t0xin include , but are not 11mited to , de1etion or conserVatiVe amino acid substitution Variants of SEQ lD NO : l. As used herein , a c0nserVatiVe Variant refers t0 alterati0ns in the amino acid sequence that do not adVersely substantially aﬁect the bi0logical functions of the peptide. A substitution , insertion or deletion is said to adVerse1y alfect the peptide When the a1tered sequence substantia1ly preVents 0r disrupts a bi01ogica1 function ass0 - ciated With the peptide ( e. g. , binding t0 a cancer cel1 ) . F0r example , the 0Verall charge , structure or hydroph0bic / hy - dr0philic properties 0f the peptide can be altered With0ut adVersely aﬁecting a bi010gical actiVity. Acc0rdingly , the amino acid sequence can be altered , f0r example to render the peptide more hydrophobic or hydrophi1ic , Without adVerse1y alfecting the bio1ogica1 actiVities of the peptide. [ 0046 ] The meth0ds 0f the inVenti0n include corresponding p0lypeptide toxins 0f other scorpi0n species that display simi1ar or re1ated actiVity to ch10r0t0xin for the diagnosis and treatment of diseases associated With abnorma1 cel1 proliferation as described herein , including cancer. For purposes of the speciﬁcati0n , “similar or related actiVity t0 chl0rot0xin” is deﬁned as binding t0 cells displaying abnormal cell gr0Wth , including benign cells exhibiting abnormal gr0Wth and malignant cancer cel1s. Examples 0f such p01ypeptide t0xins inc1ude , but are not 11mited t0 , t0xins Which c0ntain one 0r more 0f the binding domains 0f ch10rot0xin set f0rth in SEQ lD NO : 8 0r SEQ lD NO : 13 , and any of the consensus sequences set forth in Tab1e 1. TABLE 1. . Scorpion toxin alignments ( sequence identiﬁer in parenthesis ) . . Small Toxin ( Peptide I ) — Mesobuthus tamulus sindicus l 36 CthrOtOXin ( SEQ ID NO : l ) MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLGR. Small Toxin. Consensus. ( SEQ ID NO : 15 ) . ( SEQ ID NO : 16 ) . RCKPCFTTDPQMSKKCADCCGGKGKGKCYGPQCLC—. C PCFTTD QMAKKC DCCGGKGKGKCYGPQCLC. Probable Toxin LQH 8 / 6 - Leiurus quinquestriatus hebraeus. Chlorotoxin Toxin LQH. Consensus. ( SEQ ID NO : 1 ) ( SEQ ID NO : 17 ) . ( SEQ ID NO : 18 ) . l 38 MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR— - . RCSPCFTTDQQMTKKCYDCCGGKGKGKCYGPQCICAPY. C PCFTTD QM KKC DCCGGKGKGKCYGPQCIC. Chinese Scorpion - Mesobuthus martensii. Chlorotoxin ( SEQ ID NO : 1 ) E —————————————————————— MCMPCFTTDHQE Chinese ( SEQ ID NO : l9 ) MKFLYGIVFIALFLTVMFATQTDGCGPCFTTDANM Consensus ( SEQ ID NO : 20 ) C PCFTTD NM 36 61 Chlorotoxin ( SEQ ID NO : l ) ARKCDDCCGGKGRGKCYGPQCLCR—— Chinese ( SEQ ID NO : 19 ) ARKCRECCGGIG - —KCFGPQCLCNRI Consensus ( SEQ ID NO : 20 ) ARKC DCCGG G KCFGPQCLC l 35 Chlorotoxin ( SEQ ID NO : 1 ) ——————————————————————— MCMPCFTTDHQM. US 2006 / 0166892 A1. TABLE l—continued. . Scorpion toxin alignments ( sequence identiﬁer in parenthesis ) . . Chinese ( SEQ ID NO : 2l ) MKFLYGIVFIALFLTVMFATQTDGCGPCFTTDANM Consensus ( SEQ ID NO : 22 ) C PCFTTD NM. 36 59 Chl0r0t0Xin ( SEQ ID NO : l ) ARKCDDCCGGKGRGKCYGPQCLCR Chinese ( SEQ ID NO : 2l ) ARKCRECCGGIGKCFGPQCLCNRI Consensus ( SEQ ID NO : 22 ) ARKC DCCGG GK C Insect toxin I5 ( lesser Asian Scorpion ) — Mesobuthus eupeus. l 37 CthrOtOXin ( SEQ ID NO : l ) MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCRtOXin I5 ( SEQ ID NO : 23 ) MCMPCFTTDPNMANKCRDCCGG—GK—KCFGPQCLCNR COnSenSuS ( SEQ ID NO : 24 ) MCMPCFTTD NMA KC DCCGG GK KCFGPQCLC. l 36 CthrOtOXin ( SEQ ID NO : l ) MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR tOXin I5 ( SEQ ID NO : 25 ) MCMPCFTTDPNMANKCRDCCGGGKKCFGPQCLCNRConsensus ( SEQ ID NO : 26 ) MCMPCFTTD NMA KC DCCGG K C Insectotoxin Il ( lesser Asian Scorpion ) — Mesobuthus eupeus CthrOtOXin ( SEQ ID NO : l ) MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCRf§ tOXin Il ( SEQ ID NO : 27 ) MCMPCFTTRPDMAQQCRACCKG——RGKCFGPQCLCGYD Consensus ( SEQ ID NO : 28 ) MCMPCFTT MA C CC G RGKCFGPQCLC. l 36 CthrOtOXin ( SEQ ID NO : l ) MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR tOXin Il ( SEQ ID NO : 29 ) MCMPCFTTRPDMAQQCRACCKGRGKCFGPQCLCGYD Consensus ( SEQ ID NO : 30 ) MCMPCFTT MA C CC GKGK C. Insectotoxin l5A ( lesser Asian Scorpion ) — Mesobuthus eupeus. l 37 CthrOtOXin ( SEQ ID NO : l ) MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCRtoXin l5A ( SEQ ID NO : 3l ) MCMPCFTTDPNMAKKCRDCCGGNG - - KCFGPQCLCNR Consensus ( SEQ ID NO : 32 ) MCMPCFTTD NMAKKC DCCGG G KCFGPQCLC. l 36 ChlorotoXin ( SEQ ID NO : l ) MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR tOXin l5A ( SEQ ID NO : 33 ) MCMPCFTTDPNMAKKCRDCCGGNGKCFGPQCLCNRConsensus ( SEQ ID NO : 34 ) MCMPCFTTD NMAKKC DCCGG GK C. Neurotoxin P2 ( Moroccan scorpion ) - Androctonus mauretanicus. ChlorotoXin ( SEQ ID NO : l ) MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCRff NeurOtOxin ( SEQ ID NO : 35 ) —CGPCFTTDPYTESKCATCCGG——RGKCVGPQCLCNRI COnsenSuS ( SEQ ID NO : 36 ) C PCFTTD KC CCGG RGKC GPQCLC. l 36 CthrOtOXin ( SEQ ID NO : l ) MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR NeurotOxin ( SEQ ID NO : 37 ) - CGPCFTTDPYTESKCATCCGGRGKCVGPQCLCNRI Consensus ( SEQ ID NO : 38 ) C PCFTTD KC CCGGKGK C. Alignment of Chlorotoxin with all above scorpion toxins l 50 CthrOtOXin ——————————————————————— MCMPCFTTDHQMARKCDDCCGGKGRGK. Jul 27 , 2006. US 2006 / 0166892 A1. TABLE. l—continued. . Scorpion toxin alignments ( sequence identiﬁer in parenthesis ) . . Small TOXin ——————————————————————— RCKPCFTTDPQMSKKCADCCGGKGKGK TOXin LQH ——————————————————————— RCSPCFTTDQQMTKKCYDCCGGKGKGK Chinese MKFLYGIVFIALFLTVMFATQTDGCGPCFTTDANMARKCRECCGGIG——K tOXin I5 ——————————————————————— MCMPCFTTDPNMANKCRDCCGGGK——K tOXin Il - - - - - - - - - - - - - - - - - - - - - - - MCMPCFTTRPDMAQQCRACCKGRG - - K tOXin l5A ——————————————————————— MCMPCFTTDPNMAKKCRDCCGGNG——K Neurotoxin ———————————————————————— CGPCFTTDPYTESKCATCCGGRG——K COnSenSuS MCMPCFTTDPNMAKKCRDCCGGKG K. 51 61 CthrOtOXin ( SEQ ID NO : l ) CYGPQCLCR—— Small TOXin ( SEQ ID NO : l5 ) CYGPQCLC——— TOXin LQH ( SEQ ID NO : l7 ) CYGPQCICAPY Chinese ( SEQ ID NO : l9 ) CFGPQCLCNRI tOXin I5 ( SEQ ID NO : 25 ) CFGPQCLCNRtOXin Il ( SEQ ID NO : 29 ) CFGPQCLCGYD tOXin l5A ( SEQ ID NO : 33 ) CFGPQCLCNRNeurotoxin ( SEQ ID NO : 37 ) CVGPQCLCNRI Consensus ( SEQ ID NO : 39 ) CFGPQCLCNR Alignment of Chlorotoxin with toxins not requiring 93PS to align. l 38 Cthr0t0Xin ( SEQ ID NO : l ) MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR—— Small TOXin ( SEQ ID NO : l5 ) RCKPCFTTDPQMSKKCADCCGGKGKGKCYGPQCLC——— TOXin LQH ( SEQ ID NO : l7 ) RCSPCFTTDQQMTKKCYDCCGGKGKGKCYGPQCICAPY Consensus ( SEQ ID NO : 40 ) RC PCFTTD QMSKKC DCCGGKGKGKCYGPQCLC. Alignment of Chlorotoxin with toxins requiring gaps ( gaps remoVed ) . Chlorotoxin ———————————————— _______ MCMPCFTTDHQMARKCD— DCCGGKGRGK. CT - Neurotox MKFLYGIVFIALFLTVM— FATQTDGCG—. PCFTTDANMARKCRECCGGIGKCF. toxin I5 ________________ _______ MCMPCFTTDPNMAN— KCRDCCGGGKKCF. Jul 27 , 2006. US 2006 / 0166892 A1 Jul 27 , 2006. TABLE l—continued. . Scorpion toxin alignments ( sequence identiﬁer in parenthesis ) . . toxin Il ————————————————. ——————— MCMPCFT—. TRPDMAQQCRACCK—. GRGKCF toxin lSA - - - - - - - - - - - - - - - - . _______ MC—. MPCFTTDPN—. MAKKCRDCCGGNGKCF Neurotoxin ————————————————. ________ CG—. PCFTTD—. PYTESKCATCCGGRGKCV Consensus MCMPCFTTDPNMARKCRDCCGGRGKCF. 51. Chlorotoxin ( SEQ ID NO : l ) CYGPQCLCR CT - Neurotox ( SEQ ID NO : 19 ) GPQCLCNRI toxin I5 ( SEQ ID NO : 25 ) GPQCLCNRtoxin Il ( SEQ ID NO : 29 ) GPQCLCGYD toxin lSA ( SEQ ID NO : 33 ) GPQCLCNRNeurotoxin ( SEQ ID NO : 37 ) GPQCLCNRI Consensus ( SEQ ID NO : 4l ) GPQCLCNR. Chlorotoxin Peptide 8 alignment with other scorpion toxins l. Pep8 - Cth ( SEQ ID NO : 42 ) CGGKGRGKCY. Pep8—SCXl_BUTSI ( SEQ ID NO : 43 ) CGGKGKGKCY. Consensus ( SEQ ID NO : 43 ) CGGKGKGKCY. l Pep8—Ctlx ( SEQ ID NO : 42 ) CGGKGRGKCY. Pep8—SCX8_LEIQH ( SEQ ID NO : 43 ) CGGKGKGKCY. Consensus ( SEQ ID NO : 43 ) CGGKGKGKCY l lZ Pep8—Ctlx ( SEQ ID NO : 42 ) CGGKGRGKCY——. Pep8—AF079059_2 ( SEQ ID NO : 44 ) CGGIG——KCFGP Consensus ( SEQ ID NO : 45 ) CGG GRGKCFGP. l Pep8—Cth ( SEQ ID NO : 42 ) CGGKGRGKCY. Pep8 - AF079059_2 ( SEQ ID NO : 44 ) CGGIGKCFGP. Consensus ( SEQ ID NO : 46 ) CGG GK 1 lZ Pep8—Ctlx ( SEQ ID NO : 42 ) CGGKGRGKCY—— Pep8—JNO361 ( SEQ ID NO : 47 ) CGG—GK—KCFGP Consensus ( SEQ ID NO : 48 ) CGGKGKGKCFGP l Pep8 - Ctlx ( SEQ ID NO : 42 ) CGGKGRGKCY. Pep8—JNO36l ( SEQ ID NO : 47 ) CGGGKKCFGP. US 2006 / 0166892 A1 Jul 27 , 2006. TABLE l—continued. . Scorpion toxin alignments ( sequence identiﬁer in parenthesis ) . . Consensus ( SEQ ID NO : 49 ) CGG K 1 l2 Pep8—Ctlx ( SEQ ID NO : 42 ) CGGKGRGKCY——. Pep8—SCXl_BUTEU ( SEQ ID NO : 50 ) ——CKGRGKCFGP Consensus ( SEQ ID NO : 5l ) CG KGRGKCFGP. l Pep8—Cth ( SEQ ID NO : 42 ) CGGKGRGKCY. Pep8—SCXl_BUTEU ( SEQ ID NO : 50 ) CKGRGKCFGP. Consensus ( SEQ ID NO : 52 ) C GKGK 1 l2 Pep8—Ctlx ( SEQ ID NO : 42 ) CGGKGRGKCY——. Pep8—SCX5_BUTEU ( SEQ ID NO : 53 ) CGGNG——KCFGP Consensus ( SEQ ID NO : 54 ) CGG GRGKCFGP. l Pep8—Cth ( SEQ ID NO : 42 ) CGGKGRGKCY. Pep8—SCX5 , BUTEU ( SEQ ID NO : 53 ) CGGNGKCFGP. Consensus ( SEQ ID NO : 55 ) CGG GK 1 lZ Pep8—Ctlx ( SEQ ID NO : 42 ) CGGKGRGKCY——. Pep8 - SCXP_ANDMA ( SEQ ID NO : 56 ) CGG - - RGKCVGP Consensus ( SEQ ID NO : 57 ) CGGKGRGKC GP. 1 Pep8 - Ctlx ( SEQ ID NO : 42 ) CGGKGRGKCY. Pep8—SCXP , ANDMA ( SEQ ID NO : 56 ) CGGRGKCVGP. Consensus ( SEQ ID NO : 58 ) CGGKGK l lZ Pep8—Ctlx ( SEQ ID NO : 42 ) CGGKGRGKCY——. Pep8 - SCX1_BUTSI ( SEQ ID NO : 43 ) CGGKGKGKCY - — Pep8 - SCX8_LEIQH ( SEQ ID NO : 43 ) CGGKGKGKCY - — Pep8—AFO79059i2 ( SEQ ID NO : 44 ) CGG——IGKCFGP Pep8—JN036l ( SEQ ID NO : 47 ) CGG——GKKCFGP Pep8 - SCX1_BUTEU ( SEQ ID NO : 50 ) CKG - —RGKCFGP Pep8—SCX5_BUTEU ( SEQ ID NO : 53 ) CGG——NGKCFGP Pep8—SCXPiANDMA ( SEQ ID NO : 56 ) CGG——RGKCVGP Consensus ( SEQ ID NO : 59 ) CGG RGKCFGP. 1 Pep8—Ctlx ( SEQ ID NO : 42 ) CGGKGRGKCY. Pep8 - SCXl_BUTSI ( SEQ ID NO : 43 ) CGGKGKGKCY Pep8—SCX8_LEIQH ( SEQ ID NO : 43 ) CGGKGKGKCY Pep8—AF079059_2 ( SEQ ID NO : 44 ) CGGIGKCFGP. Pep8—JN036l ( SEQ ID NO : 47 ) CGGGKKCFGP. US 2006 / 0166892 A1 Jul 27 , 2006 10. TABLE l—continued. . Scorpion toxin alignments ( sequence identiﬁer in parenthesis ) . . Pep8—SCXl_BUTEU ( SEQ ID NO : 50 ) CKGRGKCFGP Pep8—SCX5_BUTEU ( SEQ ID NO : 53 ) CGGNGKCFGP Pep8—SCXP_ANDMA ( SEQ ID NO : 56 ) CGGRGKCVGP Consensus ( SEQ ID NO : 60 ) CGGKGKCFGP Chlorotoxin Peptide 21 alignment with other scorpion toxins Pep2l—CltX ( SEQ ID NO : 6l ) TTDHQMARKC Pep2l—SCXl_BUTSI ( SEQ ID NO : 62 ) TTDPQMSKKC. Consensus ( SEQ ID NO : 63 ) TTD QMAKKC. 1 Pep2l—CltX ( SEQ ID NO : 6l ) TTDHQMARKC. Pep21—SCX8_LEIQH ( SEQ ID NO : 64 ) TTDQQMTKKC Consensus ( SEQ ID NO : 65 ) TTD QM KKC. l Pep21—CltX ( SEQ ID NO : 61 ) TTDHQMARKC. Pep2l—AF079059 , 2 ( SEQ ID NO : 66 ) TTDANMARKC. Consensus ( SEQ ID NO : 67 ) TTD NMARKC 1 Pep2l—cltx ( SEQ ID NO : 6l ) TTDHQMARKC Pep2l - JNO36l ( SEQ ID NO : 68 ) TTDPNMANKC Consensus ( SEQ ID NO : 69 ) TTD NMA KC 1 Pep21 - Cltx ( SEQ ID NO : 6l ) TTDHQMARKC. Pep2l—SCXliBUTEU ( SEQ ID NO : 70 ) TTRPDMAQQC Consensus ( SEQ ID NO : 71 ) TT MA C. l Pep2l—cltx ( SEQ ID NO : 6l ) TTDHQMARKC. Pep21 - SCX5_BUTEU ( SEQ ID NO : 72 ) TTDPNMAKKC Consensus ( SEQ ID NO : 73 ) TTD NMAKKC. l Pep2l - CltX ( SEQ ID NO : 6l ) TTDHQMARKC. Pep21—SCXP , ANDMA ( SEQ ID NO : 74 ) TTDPYTESKC Consensus ( SEQ ID NO : 75 ) TTD KC. 1 Pep2l—cltx ( SEQ ID NO : 6l ) TTDHQMARKC. Pep2l—SCXl_BUTSI ( SEQ ID NO : 62 ) TTDPQMSKKC Pep21 - SCX8_LEIQH ( SEQ ID NO : 64 ) TTDQQMTKKC Pep2l—AF079059 , 2 ( SEQ ID NO : 66 ) TTDANMARKC Pep2l—JN036l ( SEQ ID NO : 68 ) TTDPNMANKC Pep2l—SCXl_BUTEU ( SEQ ID NO : 70 ) TTRPDMAQQC. Pep2l—SCX5_BUTEU ( SEQ ID NO : 72 ) TTDPNMAKKC. US 2006 / 0166892 A1. TABLE l—continued. Jul 27 , 2006. . Scorpion toxin alignments ( sequence identiﬁer in parenthesis ) . . Pep2l—SCXP_ANDMA ( SEQ ID NO : 74 ) TTDPYTESKC. Consensus ( SEQ ID NO : 76 ) TTDPNMAKKC. . [ 0047 ] As used herein , the term “re1ated scorpion toxin” refers to any of the toxins or related peptides , such as those disclosed in Table l , displaying amino acid and / or nucleotide sequence identity to chlorotoxin. Examp1es of related scorpion toxins include , but are not limited to , CT neurotoxin from Mes0buthus marrensii ( GenBank Accession AAD47373 ) , Neurotoxin BmK 41 - 2 from But / 211s martensii karsch ( GenBank Accession A59356 ) , Neurotoxin Bm12 - b from Bur / 1115 marrensii ( GenBank Accession AAKl6444 ) , Pr0bable T0xin LQH 8 / 6 fr0m Leiums quinquestriams hebraeu ( GenBank Accession P55966 ) , Sma11 toxin from Mes0buthus tamu / us sindicus ( GenBank Accession P15229 ) , the sequences of Which are a11 herein incorporated by reference in their entirety. [ 0048 ] Homo1ogy or sequence identity at the nuc1eotide or amino acid sequence leVel is determined by BLAST ( Basic Local Alignment Search Tool ) analysis using the algorithm emp1oyed by the programs b1astp , b1astn , b1astx , tb1astn and tblastx ( Altschul et al. ( 1997 ) Nucleic Acids Res. 25 , 3389 - 3402 and Karlin et al. ( 1990 ) Proc. Natl. Acad. Sci. USA 87 , 2264 - 2268 , both fu11y incorporated by reference ) Which are tailored for sequence similarity searching. The approach used by the BLAST program is to ﬁrst consider similar segments , With gaps ( non - contiguous ) and Without gaps ( contiguous ) , betWeen a query sequence and a database sequence , then to eVa1uate the statistica1 signiﬁcance of a11 matches that are identiﬁed and ﬁna11y to summarize on1y those matches Which satisfy a preselected threshold of signiﬁcance. For a discussion of basic issues in similarity searching of sequence databases , see Altschul et al. ( l994 ) Nature Genetics 6 , 119 - 129 Which is fu11y incorporated by reference. The search parameters for histogram , descriptions , alignments , expect ( i. e. , the statistical signiﬁcance threshold for reporting matches against database sequences ) , cutoﬁ matrix and ﬁlter ( loW complexity ) are at the default settings. The defau1t scoring matrix used by b1astp , b1astx , tblastn , and tb1astx is the BLOSUM62 matrix ( HenikoiI et al. ( 1992 ) Proc. Natl. Acad. Sci. USA 89 , 10915 - 10919 , fully inc0rporated by reference ) , recommended for query sequences oVer eighty - ﬁVe nucleotides or amino acids in 1ength. [ 0049 ] For blastn , the scoring matrix is set by the ratios of M ( i. e. , the reWard score for a pair of matching residues ) to N ( i. e. , the pena1ty score for mismatching residues ) , Wherein the defau1t Values for M and N are + 5 and —4 , respectiVe1y. Four blastn parameters Were adjusted as folloWs : Q=10 ( gap creation penalty ) ; R=10 ( gap extension penalty ) ; Wink - 1 ( generates Word hits at eVery Winkth position along the query ) ; and gapW - 16 ( sets the WindoW Width Within which gapped alignments are generated ) . The equiVa1ent B1astp parameter settings Were Q=9 ; R=2 ; Wink=1 ; and gapW=32. A Bestﬁt comparison betWeen sequences , aVailable in the GCG package Version l0.0 , uses DNA parameters GAP=50. ( gap creation pena1ty ) and LEN=3 ( gap extension pena1ty ) and the equiValent settings in protein comparisons are GAP=8 and LEN=2. [ 0050 ] The present inVention encompasses the al1e1ic Variants , conserVatiVe substitution Variants , and the members of the scorpion toxin peptide family , haVing an amino acid sequence of at 1east about seVenty - ﬁVe percent , at 1east about eighty - ﬁVe percent , at least about ninety percent sequence , at least about ninety - ﬁVe percent , or at least about ninety - nine percent sequence identity With the entire chlorotoxin sequence set forth in SEQ lD NO : 1. ldentity or homo1ogy With respect to such sequences is deﬁned herein as the percentage of amino acid residues in the candidate sequence that are identical With the known peptides , after alignment the sequences. [ 0051 ] Fusion proteins , or N - terminal , C - terminal or internal extensions , deletions , or insertions int0 the peptide sequence shal1 not be construed as aﬁecting homology. Examp1es of such extensions inc1ude , but are not 11mited to , the fo11oWing sequences : . ( SEQ ID NO : 2 ) HHHHHHMCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR , . ( SEQ ID NO : 3 ) XMCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR , . ( SEQ ID 110 : 4 ) ﬂMCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR. [ 0052 ] The ch1orotoxin peptide Variants inc1ude peptides haVing a fragment of the amino acid sequence set forth in SEQ lD NO : 1 , haVing at least about 7 , 8 , 9 , lO , 15 , 20 , 25 , 30 , or 35 contiguous amino acid residues. The peptide Variants further inc1ude those fragments associated With the actiVity of ch1orotoxin. Such fragments , also refe1red to as polypeptides , may contain functional regions of the ch10rotoxin peptide identiﬁed as regions 0f the amino acid sequence Which correspond to knoWn peptide domains , as We11 as regions of pronounced hydrophi1icity. Variants may also include peptide with at 1east tWo core sequences linked to one another , in any order , With interVening amino acids remoVed or replaced by a 11nker sequence. The regions are all easily identiﬁable by using commonly aVailable protein sequence ana1ysis softWare such as Mac Vector ( Oxford Molecu1ar ) . [ 0053 ] Contemplated peptide Variants further include those containing predetermined mutations by , e. g. , homologous recombination , site - directed or PCR mutagenesis , and the al1eles or other natural1y occurring Variants of the fami1y of peptides ; and deriVatiVes Wherein the peptide has been coValently modiﬁed by substitution , chemical , enzymatic or other appropriate means With a moiety other than a naturally occurring amino acid ( for example a detectable moiety such. US 2006 / 0166892 A1. as an enzyme or radioisotope ) . Examples of chlorotoxin Variant peptides include , but are not limited to the folloWing sequences : . ( SEQ ID NO : 5 ) MCMPCFTTDHQMARKCDDCCGGKGRGKCFGPQCLCR , . ( SEQ ID NO : 6 ) RCKPCFTTDPQMSKKCADCCGGKGKGKCYGPQCLC , . ( SEQ ID NO : 7 ) RCSPCFTTDQQMTKKCYDCCGGKGKGKCYGPQC ICAPY . Nucleic Acids Encoding Chlorotoxin and Chlorotoxin DeriVatiVes. [ 0054 ] The present inVention further proVides nucleic acid molecules that encode chlorotoxin and chlorotoxin deriVatiVe po1ypeptides of the inVention. Such nuc1eic acid mo1 - ecu1es can be in an iso1ated form , or can be operably linked to expression contro1 e1ements or Vector sequences. The present inVention further proVides host cells that contain the Vectors Via transformation , transfection , electroporation or any other art recognized means of introducing a nuc1eic acid into a ce11. [ 0055 ] As used herein , a “rep1icon” is any genetic e1ement ( e. g. , p1asmid , chromosome , Virus ) that functions as an aut0nomous unit of DNA replication in ViVo ( i. e. , capable of replication under its 0Wn control ) . [ 0056 ] As used herein , a “Vector” is a replicon , such as plasmid , phage 0r cosmid , to Which another nucleic acid ( e. g. , DNA ) segment may be attached so as to bring about the rep1ication of the attached segment. Vectors of the inVention include Vira1 Vectors. [ 0057 ] As used herein , a “nuc1eic acid” refers to the polymeric fonn of ribonucleotide or deoxyribonucleotides ( adenine , guanine , thymine , and / or cytosine ) in either its single stranded form , or in double - stranded helix. This term refers on1y to the primary and secondary structure of the mo1ecu1e and is not 11mited to any particu1ar tertiary form. Thus , this term inc1udes sing1e - stranded RNA or DNA , double - stranded DNA f0und in linear DNA molecules ( e. g. , restricti0n fragments ) , Viruses , plasmids , and chromosomes. ln discussing the structure of particu1ar doub1e - stranded DNA mo1ecu1es , sequences may be described herein according to the norma1 conVention of giVing on1y the sequence in the 5 ' to 3 ' direction along the non - transcribed strand of DNA ( e. g. , the strand haVing a sequence homologous to the mRNA ) . [ 0058 ] A nucleic acid “coding sequence” is a doublestranded DNA sequence Which is transcribed and translated into a p0lypeptide in ViVo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5 ' ( amino ) terminus and a translation stop codon at the 3 ' ( carboxy ) terminus. A po1yadeny1ation signa1 and transcription termination sequence Will usually be located 3 ' to the coding sequence. [ 0059 ] Transcriptiona1 and translationa1 contro1 sequences are DNA regulatory sequences , such as promoters , enhancers , po1yadeny1ation signa1s , terminators , and the 11ke , that proVide for the expression of a coding sequence in a host cell. Jul 27 , 2006. [ 0060 ] As used herein , a “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a doWnstream ( 3 ' direction ) coding sequence. For purposes of deﬁning the present inVention , the promoter sequence is bounded ( inclusiVely ) at its 3 ' terminus by the transcription initiation site and extends upstream ( 5 ' direction ) to include the minimum number of bases or elements necessary to initiate transcription at leVels detectable aboVe background. Within the promoter sequence Wi1l be found a transcription initiation site , as we1l as protein binding domains responsible for the binding of RNA polymerase. Eukaryotic promoters Will often , but not alWays , contain “TATA” boxes and “CAT” boxes. [ 0061 ] A coding sequence is “under the control” of transcriptional and translational control sequences in a cel1 When RNA po1ymerase transcribes the coding sequence into mRNA , which is then trans1ated into the protein encoded by the coding sequence. [ 0062 ] A “signal sequence” can be included before the coding sequence or a signal peptide sequence from a scorpion toxin may be used. This sequence encodes a signa1 peptide , N - termina1 to the po1ypeptide , that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media. This signal peptide is clipped off by the host ce11 before the protein 1eaVes the ce11. Signa1 sequences can be found associated with a Variety of proteins natiVe to prokaryotes and eukaryotes. For instance , alpha - factor , a natiVe yeast pr0tein , is secreted from yeast , and its signal sequence can be attached to heterologous proteins to be secreted into the media ( see U. S. Pat. No. 4 , 546 , 082 ) . Further , the a1pha - factor and its ana1ogs haVe been found to secrete hetero1ogous proteins from a Variety of yeast , such as Sacchammyces and K / uyvemmyces ( EP 883123069 ; EP 0324274 publication , and EP 0301669 ) . An examp1e for use in mamma1ian ce11s is the tPA signa1 used for expressing Factor Vlllc 11ght chain. [ 0063 ] A ce11 has been “transformed” by a exogenous or hetero1ogous nucleic acid when such nucleic acid as been introduced inside the cell. The transforming nucleic acid may or may not be integrated ( coValently linked ) into chromosoma1 DNA making up the genome of the ce11. ln prokaryotes , for examp1e , the transfo1ming nuc1eic acid may be maintained on an episomal e1ement such as a p1asmid or Viral Vector. With respect to eukaryotic cells , a stably transformed cell is one in Which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter ce11s through chromosome rep1ication. This stability is demonstrated by the abi1ity of the eukaryotic cel1 to establish cell lines or clones comprised of a population of daughter cells containing the transforming nucleic acid. [ 0064 ] As used herein , a “cell line” is a clone of a primary cell that is capable of stable grthh in Vitro for many generations. As used herein , nuc1eic acid sequences disp1ay “substantia1 identity” When at 1east about 85% ( preferably at least about 90% and most preferably at least about 95% / o ) of the nucleotides match oVer the deﬁned length of the nucleotide sequences. Sequences that are substantially identica1 can be identiﬁed in a Southern hybridization experiment under , for example , stringent conditions as deﬁned for that particular system. Deﬁning appropriate hybridization conditions is Within the skill of the art. [ 0065 ] A “heterologous” region of the nucleic acid construct is an identiﬁable segment of a nucleic acid Within a. US 2006 / 0166892 A1. larger nucleic acid molecule that is not found in association With the larger molecule in nature. Thus , When the heterologous region encodes a mammalian gene , the gene Will usually be ﬂanked by DNA that does not flank the mamma - 11an genomic DNA in the genome of the source organism. Another example of a heterologous coding sequence is a construct Where the coding sequence itse1f is not found in nature ( e. g. a cDNA Where the genomic coding sequence contains introns , or synthetic sequences haVing codons diﬁerent than the natiVe gene ) . [ 0066 ] Vectors are used to simplify manipulation of the nuc1eic acids Which encode the ch10rotoxin and ch1orotoxin deriVatiVe po1ypeptides , either for preparation of 1arge quantities of nuc1eic acids for further processing ( c1oning Vectors ) or for expression of the polypeptides ( expression Vectors ) . Vectors comprise plasmids , Viruses ( including phage ) , and integrated DNA fragments ( i. e. , fragments that are integrated into the host genome by recombination ) . Cloning Vectors need not contain expression control sequences. HoWeVer , control sequences in an expression Vector include transcriptional and translational control sequences such as a transcriptiona1 promoter , a sequence encoding suitable ribosome binding sites , and sequences Which control termination of transcripti0n and translation. The expression Vector should preferably include a selection gene to facilitate the stable expression of the chlorotoxin gene and / or to identify transformed ce11s. HoWeVer , the se1ection gene for maintaining expression can be supp1ied by a separate Vector in co - transformation systems using eukaryotic host cells. [ 0067 ] Suitab1e Vectors genera11y Wi11 contain rep1icon ( origins of rep1ication , for use in non - integratiVe Vectors ) and c0ntrol sequences Which are deriVed from species compatible with the intended expression host. By the term “rep1icab1e” Vector as used herein , it is intended to encompass Vectors containing such rep1icons as We11 as Vectors Which are replicated by integration into the host genome. Transformed h0st cells are cells Which haVe been transformed or transfected with Vectors containing chlorotoxin or ch10rotoxin deriVatiVe po1ypeptide encoding nuc1eic acid. The expressed po1ypeptides may be secreted into the cu1ture supernatant , under the control of suitable processing signals in the expressed peptide ( e. g. h0mologous or heterologous signal sequences ) . [ 0068 ] Expression Vectors for host cells ordinarily include an origin of rep1ication , a promoter 10cated upstream from the ch1orotoxin or ch1orotoxin deriVatiVe po1ypeptide coding sequence , together With a ribosome binding site , a polyadenylation site , and a transcriptional termination sequence. Those of ordinary skill Will appreciate that certain of these sequences are not required for expression in certain hosts. An expression Vector for use With microbes need on1y contain an origin of rep1ication recognized by the host , a promoter Which Will function in the host , and a selection gene. [ 0069 ] Commonly used promoters are deriVed from polyoma , boVine papilloma Virus , CMV ( cytomegaloVirus , either murine or human ) , Rouse sarcoma Virus , adenoVirus , and simian Virus 40 ( SV40 ) . Other contro1 sequences ( e. g. , terminator , polyA , enhancer , or ampliﬁcation sequences ) can also be used. [ 0070 ] An expression Vector is constructed so that the ch10rotoxin or chlorotoxin deriVatiVe polypeptide coding. Jul 27 , 2006. sequence is located in the Vector With the appropriate regulatory sequences , the positioning and orientation of the coding sequence With respect to the control sequences being such that the coding sequence is transcribed and trans1ated under the “control” of the contro1 sequences ( i. e. , RNA polymerase Which binds to the DNA molecule at the control sequences transcribes the coding sequence ) . The control sequences may be ligated to the coding sequence prior to insertion into a Vector , such as the cloning Vectors described aboVe. A1tematiVe1y , the coding sequence can be c1oned directly into an expression Vector which already contains the contro1 sequences and an appropriate restriction site. lf the se1ected host ce11 is a mamma1ian ce11 , the contro1 sequences can be hetero1ogous or homologous to the ch10rotoxin or ch10rotoxin deriVatiVe po1ypeptide coding sequence , and the coding sequence can either be genomic DNA containing introns or cDNA. 0071 8xpres ] s the proteins of the present inVention , Whether from Vertebrate or inVertebrate ce11s , inc1uding insects , and the procedures of propagation thereof are knoWn. [ 0072 ] Other expression Vectors are those for use in eukaryotic systems. An exemp1ary eukaryotic expression system is that employing Vaccinia Virus , Which is we1l - knoWn in the art ( see , f0r example , WO 86 / 07593 ) . Yeast expression Vectors are knoWn in the art ( see , for example , U. S. Pat. Nos. 4 , 446 , 235 and 4 , 430 , 428 ) . Another expression system is Vector pHSl , Which transforms Chinese hamster oVary ce11s ( see WO 87 / 02062 ) . Mammalian tissue may be cotransf0rmed With DNA encoding a selectable marker such as dihydrofolate reductase ( DHFR ) or thymidine kinase and DNA encoding the ch1orotoxin or ch10rotoxin deriVatiVe po1ypeptide. lf Wi1d type DHFR gene is employed , it is preferable to select a host cell Which is deﬁcient in DHFR , thus permitting the use of the DHFR coding sequence as marker for successful transfection in hgt medium , Which 1acks hypoxanthine , g1ycine , and thymidine. [ 0073 ] Depending on the expression system and host se1ected , ch10rotoxin or ch10rotoxin deriVatiVe po1ypeptide are produced by groWing host ce11s transformed by an exogenous or hetero1ogous DNA construct , such as an expression Vector described aboVe under conditions Whereby the polypeptide is expressed. The chlorotoxin or ch10rotoxin deriVatiVe polypeptide is then isolated from the host ce11s and puriﬁed. lf the expression system secretes the protein or peptide into the grthh media , the protein can be puriﬁed directly from cell - free media. The selection of the appropriate grthh conditions and initial crude recoVery methods are within the skill of the art. [ 0074 ] Once a coding sequence for a chlorot0xin or chlorotoxin deriVatiVe polypeptide of the inVention has been prepared or iso1ated , it can be c1oned into any suitab1e Vector and thereby maintained in a composition of cells Which is substantia1ly free of cel1s that do not contain any ch1orotoxin coding sequence. As described aboVe , numerous cloning Vectors are knoWn to those of ski1l in the art. Higher eukaryotic cell cultures may be used to. Chlorotoxin Peptide Mimetics. [ 0075 ] ln another class of ch1orotoxin deriVatiVes , the present inVention inc1udes peptide mimetics that mimic the three - dimensional structure of chlorotoxin. Such peptide mimetics may haVe signiﬁcant adVantages oVer naturally. US 2006 / 0166892 A1. occurring peptides including , for example , more economical production , greater chemical stability , enhanced pharmacological properties ( half - life , absorption , potency , efﬁcacy , etc. ) , altered speciﬁcity ( e. g. , a broad - spectrum of biologica1 actiVities ) , reduced antigenicity and others. [ 0076 ] ln one form , mimetics are peptide - containing molecu1es that mimic elements of chlorotoxin peptide secondary structure. The underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly to orient amino acid side chains in such a Way as to faci1itate mo1ecular interactions , such as those of antibody and antigen. A peptide mimetic is expected to permit molecular interactions similar to the natural molecule. ln another form , peptide analogs are commonly produced in the pharmaceutica1 industry as non - peptide drugs With properties analogous to those of the temp1ate peptide. These types of non - peptide compounds are a1so referred to as peptide mimetics or peptidomimetics ( Fauchere ( 1986 ) AdV. Drug Res. 15 , 29 - 69 ; Veber & Freidinger ( l985 ) Trends Neurosci. 8 , 392 - 396 ; EVans et a1. ( 1987 ) J. Med. Chem. 30 , 1229 - 1239 Which are incorporated herein by reference ) and are usually deVeloped with the aid 0f computerized molecular modeling. [ 0077 ] Peptide mimetics that are structurally similar to therapeutically useﬁ11 peptides may be used to produce an equiValent therapeutic or prophylactic eﬁect. Generally , peptide mimetics are structura11y simi1ar to a paradigm po1ypeptide ( i. e. , a po1ypeptide that has a biochemica1 property or pharmacological actiVity ) , but haVe one or more peptide linkages optionally replaced by a linkage by methods knoWn in the art. Labe1ing of peptide mimetics usua11y inVo1Ves coVa1ent attachment of one or more 1abe1s , direct1y or through a spacer ( e. g. , an amide group ) , to non - interfering positions on the peptide mimetic that are predicted by quantitatiVe structure - actiVity data and molecular modeling. Such non - interfering positions genera11y are positions that do not fo1m direct contacts with the macromo1ecu1es to Which the peptide mimetic binds to produce the therapeutic eﬁect. DeriVitization ( e. g. , labeling ) of peptide mimetics should n0t substantially interfere With the desired biological or pharmaco1ogica1 actiVity of the peptide mimetic. [ 0078 ] The use of peptide mimetics can be enhanced through the use of combinatoria1 chemistry to create drug 11braries. The design of peptide mimetics can be aided by identifying amino acid mutations that increase or decrease binding of a peptide to , for instance , a tumor cell. Approaches that can be used inc1ude the yeast tWo hybrid method ( see Chien et al. ( 1991 ) Proc. Natl. Acad. Sci. USA 88 , 9578 - 9582 ) and using the phage disp1ay method. The two hybrid method detects protein - protein interactions in yeast ( Fields et al. ( 1989 ) Nature 340 , 245 - 246 ) . The phage display method detects the interaction betWeen an immobilized protein and a protein that is expressed on the surface of phages such as lambda and M13 ( Amberg et a1. ( 1993 ) Strategies 6 , 2 - 4 ; Hogrefe et al. ( 1993 ) Gene 128 , 119 - 126 ) . These methods allow positiVe and negatiVe selection for peptide - protein interactions and the identiﬁcation of the sequences that determine these interactions. Pharmaceutica1 Compositions. [ 0079 ] Pharmaceutica1 compositions of the present inVention can be administered Via parenteral , subcutaneous , intraVenous , intramuscular , intraperitoneal , intrathecal , intracra - . Ju1. 27 , 2006. nial or transdermal or buccal routes. For example , an agent may be administered locally to a tumor Via microinfusion. AlternatiVely , or concurrently , administration may be by the oral route. The dosage administered Wi11 be dependent upon the age , hea1th , and Weight of the recipient , kind of concurrent treatment , if any , frequency of treatment , and the nature of the elfect desired. [ 0080 ] ma1 ranges of eﬁectiVe amounts of each component is Within the skil1 of the art. Dosages of ch1orotoxin and / or deriVatiVes thereof of the present inVention typically comprise about l.0 ng / kg body Weight to about 0. l3 mg / kg body Weight. In one embodiment , dosages of chlorotoxin and / or deriVatiVes thereof comprise about 1.0 ng / kg body weight to about 0.1 mg / kg body Weight. ln a preferred embodiment , dosages for systemic administration comprise about 0.0l ug / kg body Weight to about 0.1 mg / kg body Weight. ln another embodiment , the dosage of ch10rotoxin and / or deriVatiVes thereof comprises 1ess than about 0.1 mg / kg body Weight. More preferred dosages for systemic administration comprise about 0. l ug / kg body Weight to about 0.05 mg / kg body Weight. ln another preferred embodiment , the dosage of ch10rotoxin and / or deriVatiVes thereof comprises 1ess than about 0.05 mg / kg body Weight. The most preferred dosages for systemic administration comprise betWeen ab0ut l.0 ug / kg body Weight to about 0.01 mg / kg b0dy Weight. In other embodiments , the amount of chlorotoxin and / or. While indiVidual needs Vary , determination of opti - . deriVatiVes thereof administered is an amount eﬁectiVe to bring the concentration of ch1orotoxin and / or deriVatiVes thereof in the serum to a c0ncentrati0n of about 20.0 , l0.0 , 5.0 , 2.50 , 1.25 , 0.625 , 0.3125 , 0.156 , 0.078 , 0.039 , 0.020 , 0.010 , 0.005 , 0.003 , 0.0015 , 0.0008 , 0.0003 or 0.0001 nM. The prefe1red dosages for direct administration to a site Via microinfusion comprise 1 ng / kg body weight to 1 mg / kg body weight. [ 0081 ] ln addition t0 chlor0toxin and / 0r deriVatiVes thereof , the compositions of the present inVention may contain suitab1e pharmaceutica11y acceptab1e carriers comprising excipients and auxiliaries that facilitate processing of the actiVe compounds into preparations Which can be used pharmaceutically for deliVery to the site 0f action. Suitable formulations for parenteral administration include aqueous so1utions of the actiVe compounds in Water - so1ub1e form , for examp1e , Water - solub1e sa1ts. ln addition , suspensions of the actiVe compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solVents or Vehicles include fatty oils , for example , sesame oil or synthetic fatty acid esters , for examp1e , ethy1 oleate or trig1ycerides. Aqueous injection suspensions may contain substances which increase the Viscosity of the suspension include , for example , sodium carboxymethyl cel1ulose , sorbito1 and dextran. Optionally , the suspension may also contain stabilizers. Liposomes can a1so be used to encapsu1ate the agent for de1iVery into the ce11. [ 0082 ] The pharmaceutical formulation for systemic administration according to the inVention may be formulated for enteral , parenteral or topical administration. lndeed , all three types of formulations may be used simu1taneously to achieVe systemic administration of the actiVe ingredient. [ 0083 ] As mentioned aboVe for some methods of the inVention , topical administration may be used. Any common topical formulation such as a solution , suspension , gel , . US 2006 / 0166892 A1. ointment or salVe and the like may be employed. Preparation of such topical formulations are described in the art of pharmaceutica1 formulations as exempliﬁed , for example , by Gennaro et a1. ( 1995 ) Remingtons Pharmaceutica1 Sciences , Mack Publishing. For topical app1ication , the compositions could also be administered as a poWder or spray , particular1y in aerosol form. ln a some embodiments , the compositions of this inVention may be administered by inha1ation. For inha1ation therapy the actiVe ingredients may be in a solution useful for administration by metered dose inhalers or in a form suitable for a dry poWder inhaler. ln another embodiment , the compositions are suitable for administration by bronchia1 1aVage. [ 0084 ] Suitable formulations for oral administration inc1ude hard or soft ge1atin capsu1es , pi11s , tab1ets , inc1uding coated tablets , e1ixirs , suspensions , syrups or inhalations and contro11ed release forms thereof. [ 0085 ] ch10rotoxin deriVatiVes that haVe one or more atoms replaced by an atom haVing an atomic mass or mass number dilIerent from the atomic mass or mass number usually found in nature , or one or more of such atoms attached to the ch10rotoxin deriVatiVes. Examp1es of isotopes that can be inc0rporated into compounds of the inVention include , but are not limited t0 , isotopes of hydrogen , carbon , ph0sphorous , iodine , rhenium , indium , yttrium , technetium and 1utetium ( i. e. , inc1uding , but not 11mited to , 3H , l4C , 3 1P , 32P , 35S , 1311I 125L 1231I lS7Re , 64Cu , 1111nI 90Y , 99mTCI 177Lu ) , others isotopes of these elements , and other isotopes knoWn in the art. Agents of the present inVention , pr0drugs thereof , and pharmaceutica11y acceptab1e sa1ts of said agents or of said prodrugs Which contain the aforementioned isotopes and / or other isotopes of other atoms are within the scope of this inVention. Tritium and carbon - l4 isotopes are particularly preferred for their ease of preparation and detectability. Further , substitution with heaVier isotopes such as deuterium can afford certain therapeutic adVantages resu1ting from greater metabo1ic stabi1ity , for examp1e increased in ViVo half - life or reduced dosage requirements and , hence , may be preferred in some circumstances. The inVention a1so inc1udes isotopica1ly - 1abe1ed. Fusion Proteins. [ 0086 ] The present inVention also includes compositions Where a cytotoxic agent is 11nked to a ch1orotoxin deriVatiVe. Examp1es of cytotoxic agents inc1ude , but are not 11mited to , gelonin , ricin , saponin , pseudonomas exotoxin , pokeweed antiViral pr0tein , diphtheria toxin , complement proteins , or any other agent knoWn in the art Which is capable of killing a ce11 upon contact With that ce11. [ 0087 ] The inVention inc1udes fusion polypeptides and salts thereof , comprising at least one second polypeptide. In some embodiments , the second polypeptide includes a cancer cell - binding domain Which speciﬁcally binds to an epitope expressed on1y on ce11s exhibiting abnorma1 grthh ( i. e. cancer ce1ls ) . The term “cancer ce1l - binding domain” refers to an amino acid sequence capable of binding or otherWise speciﬁcally associating With a ce1l displaying abnormal grthh ( e. g. , benign and malignant cancer cells ) . ln some embodiments the cancer cel1 binding - domain is an antibody Whi1e in other embodiments it is a 1igand which speciﬁca11y binds to a receptor expressed only on cancer cells. Examples of antibodies include , but are not limited to , antibodies Which speciﬁcally bind to B - cells or T - cells. Jul 27 , 2006. Examples of receptor ligands include , but are not limited to , cytokines and grthh factors including epidermal grthh factor. [ 0088 ] The second polypeptide can also include a stabilization domain Which increases the in Vitro and in ViVo ha1f - life of the fusion polypeptide. As used herein , the term “stabi1ization domain” refers to an amino acid sequence capab1e of extending the in Vitro and in ViVo ha1f - 1ife of ch10rotoxin or a chlorotoxin deriVatiVe When compared to ch10rotoxin alone. The stabilization domain can comprise human proteins ( e. g. , fu11 length or truncated , so1ub1e proteins from extracellular fragments , etc ) such as human serum albumin , transferrin or other proteins Which stabilize the in ViVo or in Vitro half - life of chlorotoxin or a chlorotoxin deriVatiVe. These additiona1 functional domains may themselVes serVe as linker peptides , for example , for joining a cancer ce1l - binding domain to ch1orotoxin or a ch1orotoxin deriVatiVe. AlternatiVely , they may be located elseWhere in the fusion molecule ( e. g. , at the amino or carboxy terminus thereof ) . ln a1tematiVe embodiments , the stabi1ization domain is a chemica1 moiety ( e. g. , PEG ( polyethy1ene g1ycol ) or a dextran ) . [ 0089 ] The te1m “fused” or “fusion po1ypeptide” as used herein refers to po1ypeptides in Which : ( i ) a giVen functiona1 domain ( i. e. a cancer cell - binding domain ) is bound at its carboxy terminus by a coValent bond either to the amino terminus of another functiona1 domain ( i. e. , an human serum a1bumin component ) or to a 11nker peptide which itse1f is bound by a coVa1ent bond to the amino te1minus of ch10rotoxin or a chlorotoxin deriVatiVe ; or ( ii ) a giVen functional domain ( i. e. a cancer cell - binding domain ) is bound at its amino terminus by a coVa1ent bond either to the carboxy terminus of another functiona1 domain ( i. e. , an human serum albumin component ) or to a linker peptide which itself is bound by a coValent bond to the carboxy terminus of chlorotoxin or a chlor0toxin deriVatiVe. [ 0090 ] Similarly , “fused” When used in connection With the nucleic acid intermediates of the inVenti0n means that the 3 ' - [ or 5 ' - ] terminus of a nuc1eotide sequence encoding a ﬁrst functiona1 domain is bound to the respectiVe 3 ' - [ or 5 ' - ] terminus of a nucleotide sequence encoding a second functional domain , either by a coValent bond or indirectly Via a nucle0tide linker Which itself is coValently bound preferably at its termini to the ﬁrst functional domain - encoding polynuc1eotide and optiona11y , a second functiona1 domainencoding nuc1eic acid. [ 0091 ] Examp1es of fusion po1ypeptides of the inVention may be represented by , but are not 11mited by , the fol1owing formulas : . R1 - L - R2 ( 1 ) R2 - L - R1 ( 11 ) R1 - L - R2 - L - R1 ( 111 ) R1 - L - R1 - L - R2 ( 1v ) R2 - L - R1 - L - R1 ( 1v ) . Wherein R1 is the amino acid sequence of a cancer cellbinding domain , R2 is the amino acid sequence of a stabi - 1izing domain ( e. g. , human serum albumin ) , each L is ch10rotoxin or a ch1orotoxin deriVatiVe Which is bound by a coValent bond to a terminus of R1 and / or R2 , Whereby the aboVe molecule fragments are read directional1y ( i. e. , With. US 2006 / 0166892 A1. the left side corresponding to the amino terminus and the right side to the carboxy terminus of the molecule ) . Methods of Treatment Using Ch10rotoxin and / or DeriVatiVe Thereof. [ 0092 ] This inVention inc1udes methods for the treatment of abnorma1 ce11 grthh in a mammal , including a human , comprising administering to said mammal an amount of ch10rotoxin and / or deriVatiVes thereof , an amount of a fusion protein comprising chlorotoxin or a deriVatiVe thereof , or a pharmaceutica1 composition comprising an amount of chlorotoxin and / or deriVatiVes thereof , that is eﬁectiVe in inhibiting or arresting the grthh of abnorma1ly proliferating cells , such as cancer cells , Without the addition of other therapeutic agents. ln one embodiment of this method , the abnorma1 ce1l grthh is cancer , inc1uding , but not 1imited to , prostate cancer , breast cancer , lung cancer , non - small cell lung carcinoma , bone cancer , liVer cancer , pancreatic cancer , skin cancer , cancer of the head or neck , cutaneous or intraocular me1anoma , uterine cancer , oVarian cancer , recta1 cancer , cancer of the ana1 region , stomach cancer , colon cancer , uterine cancer , carcinoma of the fallopian tubes , carcinoma of the endometrium , carcinoma of the cervix , carcinoma of the Vagina , carcinoma of the Vu1Va , Hodgkins Disease , cancer of the esophagus , cancer of the smal1 intestine , cancer of the endocrine system , cancer of the thyr0id gland , cancer of the parathyroid gland , cancer of the adrenal gland , sarcoma of soft tissue , cancer of the urethra , cancer of the penis , chronic or acute 1eukemia , 1ymphocytic 1ymphomas , cancer of the b1adder , cancer of the kidney or ureter , renal cell carcinoma , carcinoma of the renal pelVis , neoplasms of the central nerV0us system ( CNS ) , neuroectoderma1 cancer , spina1 axis tumors , g1ioma , meningioma , pituitary adenoma , or a combination of one or more of the foregoing cancers. ln another embodiment of said method , said abnormal cell grthh is a benign proliferatiVe disease , including , but not limited to , psoriasis , benign prostatic hyperp1asia , hypertrophy or restinosis. [ 0093 ] This inVention a1so inc1udes methods for the treatment of abno1ma1 ce11 growth in a mamma1 Which comprises administering to said mammal , including a human , a pharmaceutical composition comprising an amount of chl0rotoxin and / or deriVatiVes thereof that is eﬁectiVe in inhibiting abnorma1 ce11 growth. This inc1udes the abnorma1 grthh and / or proliferation of cancer cells inc1uding benign and malignant cells of neoplastic diseases. lnhibition of abnormal cell growth can occur by a Variety of mechanism including , but not limited to , cell death , apoptosis , inhibition of ce11 diVision , transcription , trans1ation , transduction , etc. [ 0094 ] ln practicing the methods of this inVention , chlorotoxin and / or deriVatiVes thereof may be used alone or in combination With other inactiVe ingredients. As discussed aboVe , the present inVention includes compositions and methods Where a drug or cytotoxic agent is 11nked to a ch10rotoxin deriVatiVe. The methods of the inVention therefore include administration of a chlorotoxin deriVatiVe linked to a cytotoxic agent for the treatment of a disease associated With abnormal ce1l grthh , including cancer. Examp1es of cytotoxic agents inc1ude , but are not 11mited to , ge1onin , ricin , saponin , pseudonomas exotoxin , pokeweed antiViral protein , diphtheria toxin , complement proteins , or any other agent knoWn in the art Which is capable of killing a cel1 upon contact With that cell. Jul 27 , 2006. [ 0095 ] The compositions and methods of the inVention can be utilized in ViVo , ordinarily in mammals , such as humans , sheep , horses , cattle , pigs , dogs , cats , rats and mice or in Vitro. The inVention is particu1arly useful in the treatment of human subjects. [ 0096 ] Without further description , it is belieVed that one of ordinary ski1l in the art can , using the preceding description and the folloWing illustratiVe examples , make and utilize the compounds of the present inVention and practice the claimed methods. The folloWing Working examples describe embodiments of the present inVention , and are not to be construed as limiting in any Way the remainder of the disclosure. EXAMPLE 1. [ 0097 ] D54 glioblastoma cells Were plated at a density of about 1000 cells / Well in a 96 - Well ﬁat bottom plate and incubated in 5% CO2 at 37° C. After twenty - four hours ch10rotoxin was added at 1 : 4 11miting di1utions to a ﬁna1 concentration of 20 , 5 , l.25 , 0.313 , 0.078 , 0.0l95 , 0.0049 , 0.00l2 , 0.00031 or 0.00008 nM. Control cells receiVed Vehicle only. TWenty - four hours after treatment , the eﬁect of ch10rotoxin Was quantiﬁed using the MlT mitochondria1 enzyme substrate with the Ce1l Counting Kit - 8 ( CCK - 8 ) ( Dojind0 Inc. ) according to the manufacturers instructions. In brief , folloWing the treatment period With chlorotoxin , ce11s Were incubated With CCK - 8 reagent. After incubation , p1ates were read on a microp1ate reader at a WaVe1ength of 490 nm , with higher absorbance indicating greater cel1 Viability. FIG. 1 shows that chlorot0xin incubation inhibited proliferation of the D54 cells at all concentrations tested doWn through 0.00120 nM as eVidenced by the 10wer number of Viab1e ce11s / We11 Versus PBS contro1. EXAMPLE 2. [ 0098 ] D54 g1iob1astoma ce11s Were p1ated at a density of about 1000 cells / Well in a 96 - Well ﬁat bottom plate and incubated in 5% CO2 at 37° C. After twenty - four hours ch10rotoxin Was added at l : 4 limiting dilutions to a ﬁnal concentration ( in nM ) of 20 , 5 , 1.25 , 0.313 , 0.078 , 0.02 , 0.0049 , 0.0012 , 0.0003 , or 0.00008. Contro1 ce11s receiVed Vehicle only. After tWenty - four hours , half of the cells Were Washed free of chlorotoxin , the medium replaced With fresh medium. Cells in both conditions , chlorotoxin left on and ch10rotoxin remoVed , Were incubated for an additiona1 four days. Fo11oWing incubation , the eﬁect of ch10rotoxin Was quantiﬁed using the MTT mitochondrial enzyme substrate With the CCK - 8 as in Example l. FIG. 2 shoWs that the long incubation time alloWed the cells to oVercome the eﬁfects of ch10rotoxin With the additiona1 days of pro1iferation and ch10rotoxin did not appear to inhibit ce1l pro1iferation in this instance. EXAMPLE 3. [ 0099 ] PC3 prostate cancer cells Were plated at a density of about 1000 ce1ls / We1l in a 96 - Well ﬂat bottom plate and incubated in 5% CO2 at 37° C. After twenty - four hours ch10rotoxin was added at 1 : 2 11miting di1utions to a ﬁna1 concentration ( nM ) of 20 , 10 , 5 , 2.5 , 1.25 , 0.625 , 0.313 , 0.156 , 0.078 , and 0.039. Contro1 ce1ls receiVed PBS Vehic1e on1y. TWenty - four hours after treatment , the elfect of chlorotoxin Was quantiﬁed using the MTT mitochondrial. US 2006 / 0166892 A1. enzyme substrate With the CCK - 8 as in Example 1. FIG. 3 shoWs that chlorotoxin incubation inhibited proliferation of the D54 cells at all concentrations tested as eVidenced by the 10wer number of Viab1e ce1ls / we1l Versus PBS c0ntro1. EXAMPLE 4. [ 0100 ] Three groups of eight athymic nude mice receiVed a subcutaneous injection 0f 5><107 human D54 glioblastoma cells in their right flank to produce human glioma ﬂank xen0grafts in these mice. Anima1s in Groups 1 and III receiVed 2.6 ug chl0r0toxin ( SEQ lD NO : 1 ) in 100 111 phosphate - buﬂered sa1ine intraVenous1y at 14 , 21 , 28 , 35 , 42 and 49 days after D54 injection. Animals in Groups II and III receiVed 2 Gy 60C Whole - body irradiation at 15 , 22 , 29 , 36 , 43 and 50 days after D54 injection. Tum0r size was measured three times Weekly and is depicted in FIG. 4. EXAMPLE 5. [ 0101 ] lntracranial D54MG gli0ma xen0 grafts Were established in athymic nude mice by the implantation of 1><l06 D54MG ce11s in the brain of each subject. A treatment regimen was begun 14 days post - imp1antati0n With tail Vein intraVenous injections two times per Week. The control group 0f seVen mice Were administered saline Vehicle only. A second group of mice , comprising eight animals , were each administered a 10W dose of ch10rot0xin of 0.2 ug / dose and a third group 0f mice , comprising eight animals , were administered a high d0se 0f chlor0toxin 0f 2.0 ug / d0se. Animals Were f0lloWed until death and surViVal time was plotted 0n a Kaplan - Meier chart , indicating median surViVal ( FIG. 5 ) . These resu1ts indicate that treatment With ch1orotoxin a10ne substantia11y extends the 11fe 0f a subject in an intracranial model and that this enhanced surViVal may be d0se dependent. It is notable that administration 0f chl0rotoxin was intraVenous , demonstrating that ch1orotoxin crosses the b1ood - brain barrier t0 exert its eﬂect. EXAMPLE 6. [ 0102 ] ln a separate inVestigation , D54MG glioma xen0gEafts Were established peripherally by implanting lO><10 D54MG cells in the flanks of athymic nude mice. Tumors were pa1pab1e at 14 days , With indiVidua1 tumor V01umes 0f appr0ximate1y 43 mm3. Again , the treatment regimen was begun 14 days post - imp1antation With tail Vein intraVenous injections two times per Week. The control group of seVen mice Were administered saline Vehicle on1y. A second group of mice , comprising eight anima1s , were each administered a loW d0se of ch1or0toxin of 0.2 ug / dose. Tumor size Was measured at the time of each injection , and pl0tted as a percent 0f original tumor size ( FIG. 6 ) . lntraVenous treatment Was ended at 42 days and the measurement of the tumors Was continued for seVera1 Weeks. These resu1ts demonstrate that 10W - dose ch10rotoxin alone can dramati - ca11y decrease the tumor grthh in this ﬂank mode1. EXAMPLE 7. [ 0103 ] To identify core binding site sequences of chlorotoxin , twenty - seVen oVerlapping lO - mers deriVed from SEQ 1 ) NO : 1 Were synthesized , starting fr0m the C - terminus of the peptide as indicated in FIG. 7. Each peptide had a biotin attached at the amino tenninus to facilitate detection and each cysteine residue Was replaced With a serine in order to preVent cross - linking. Jul 27 , 2006. [ 0104 ] Binding of the 10 - mer peptides to PC3 prostate cancer ce11s in Vitr0 Was measured by incubating cu1tured PC3 cells With indiVidual peptides. Binding Was detected and quantiﬁed by incubating the peptide exposed cells With HRP - aVidin using a c0mmercia1 kit according to manufacturers instructions. [ 0105 ] FIG. 8 shoWs that the lO - mer peptide 4 of SEQ lD NO : 1 does not bind to PC3 , indicating that the lysine residue Which starts peptide 5 must be the start 0f the binding site. Peptides 5 - 8 bind , but the binding is lost in peptide 9. This suggests that the tyrosine residue is another key , since this is present in peptide 8 but 10st in peptide 9. This indicated that a ﬁrst binding region of chlorotoxin resides Within the 7 - mer sequence KGRGKSY ( SEQ ID NO : 8 ) residing at amin0 acid residues 23 - 29 of SEQ lD NO : 1 Which are comm0n to peptides 5 - 8. [ 0106 ] FIG. 9 shoWs that peptide 19 of SEQ lD NO : 1 d0es not bind PC3 cells but peptide 20 d0es , indicating that the threonine residue Which starts peptide 20 may be the start 0f a sec0nd binding site because peptides 20 - 24 bind most strongly. Binding decreases again in peptide 25 , suggesting that the peptide 24 terminal arginine residue is an0ther key , since this is present in peptide 24 but 10st in peptide 25. This indicates that a second binding region of chlorotoxin resides Within the 9 - mer sequence TDHQMAR ( SEQ lD NO : 9 ) residing at amino acid residues 8 - 14 0f SEQ lD NO : 1 which are common to peptides 20 - 24. The binding in this second core sequence is broader , Which may be a reﬂection of Very simi1ar amino acids present at the ends of the regi0n. F0r example , there are tW0 threonine residues at peptides 20 and 21 , and there is a lysine at the end of peptide 22 next to the arginine residue. EXAMPLE 8. [ 0107 ] T0 determine the in ViV0 actiVity 0f these identiﬁed binding regi0ns , lO - mer peptides 5 ( amin0 acid residues 23 - 32 ) , 12 ( amino acid residues 16 - 25 ; as a negatiVe contro1 ) and 21 ( amin0 acid residues 7 - 16 ) of SEQ lD NO : 1 Were used in a crayﬁsh paralysis assay , an assay which is commonly used to determine the bi0 - actiVity of chl0r0t0xin ( see DeBin et al. ( 1993 ) Am. J. Physiol. 264 , C361 - 369 ) . Peptides 5 and 12 fai1ed to para1yze crayﬁsh , Whi1e peptide 21 Was eﬂectiVe , indicating that the site Which is resp0nsib1e f0r the para1ytic effect of ch1orotoxin is the region deﬁned by peptide 21. [ 0108 ] Additional1y , seVera1 of the ch10rotoxin deriVatiVes Were each analyzed in the crayﬁsh assay and compared to chl0r0t0xin ( Table 2 ) . Each 0f these deriVatiVes c0mprises the putatiVe end - amino acids , the T and the R Within the sequence corresponding to peptide 21. TABLE 2. . CraySEQ ﬂsh Peptide ID Assay Identity Sequence Comparison. . Cltx 1 Yes 100% TDHQMAR ( SEQ ID NO : 9 ) Cltx 5 Yes 100s TDHQMAR ( SEQ ID NO : 9 ) ( Y / F ) . US 2006 / 0166892 A1. TABLE 2—continued. . CraySEQ ﬁsh Peptide ID Assay Identity Sequence Comparison. . STP—l 6 Yes 7l.4% TDPQMSR ( SEQ ID NO : 77 ) . 6xH—CltX 2 Yes 100% TDHQMAR ( SEQ ID NO : 9 ) Y—Cltx 3 Yes lO0% TDHQMAR ( SEQ ID NO : 9 ) . YSY—CltX 4 Yes lO0% TDHQMAR ( SEQ ID NO : 9 ) . . EXAMPLE 9. [ 0109 ] Ch1or0toxin is a 36 - amino acid peptide with 8 cysteines , depicted be1oW in b01d type with the sequences of peptide number 8 ( beta - region peptide ) and peptide number 2l ( alpha - region peptide ) identiﬁed using the 0Verlapping lO - mers in Example 8 underlined : . MCMPCFTTDHQMARKCDDCCGGKGRCKCYGPQCLCR ( SEQ ID NO : l ) . [ 0110 ] ln 0rder to conﬁrm the identify the minima1 binding sequences Within the a1pha and beta peptides , the entire peptides Were synthesized as a 10 - mer With a biotin at the amino terminus as Well as shorter sequences reducing the size of the peptide by one amino acid at the amino terminus each time. [ 0111 ] F0r the beta peptide , the sequences 0f peptide 8 noted in Tab1e 3 were eVa1uated and probed for binding to U251 g1ioma ce11s : . . . TABLE 3 Peptide Sequence 8 BiOtin—GGKGRGKSYG ( SEQ ID NO : 78 ) 8a BiOtin—GKGRGKSYG ( SEQ ID NO : 79 ) 8b BiOtin - KGRGKSYG ( SEQ ID NO : 80 ) 8C BiOtin—GRGKSYG ( SEQ ID NO : 81 ) . . [ 0112 ] For the alpha peptide , the sequences of peptide 21 noted in Tab1e 4 were eVa1uated and probed for binding to U251 glioma cel1s : . . . . TABLE 4. Peptide Sequence. 21 Biotin—TTDHQMARKS ( SEQ ID no : 82 ) 2la Biotin—TDHQMARKS ( SEQ ID no : 10 ) 21b Biotin - DHQMARKS ( SEQ ID no : 83 ) 21c Biotin—HQMARKS ( SEQ ID no : 84 ) 21d Biotin—QMARKS ( SEQ ID no : 85 ) . [ 0113 ] Results demonstrated that the initial threonine resi - . due of the alpha - region peptide is detrimental to binding but. Jul 27 , 2006. that the second threonine is crucial to binding. It was also discoVered that none of the smaller peptides exhibit binding as strong as the 9 - mer of peptide 21a. EXAMPLE lO. [ 0114 ] binding properties of the a1pha peptide , alanine scan Variants Were synthesized by replacing each amino acid of the 9 - mer peptide TDHQMARKS ( SEQ lD NO : lO ) sequentially as depicted in Table 5. Peptide 21 , the natiVe c0re 9 - mer , and each alanine - substituted 9 - mer peptide Was synthesized With a biotin at the amin0 terminus and eValuated f0r their. binding Versus b0th U251 and PC3 ce1ls ( FIG. 10 ) . To determine the contribution of each residue to the. . . . TABLE 5. Peptide Sequence. 21 Biotin—TTDHQMARKS ( SEQ ID no : 82 ) 21a Biotin—TDHQMARKS ( SEQ ID no : 10 ) 21a—A1 Biotin—ADHQMARKS ( SEQ ID no : 86 ) 21a—A2 Biotin—TAHQMARKS ( SEQ ID no : 87 ) 21a—A3 Biotin—TDAQMARKS ( SEQ ID no : 88 ) 21a—A4 Biotin—TDHAMARKS ( SEQ ID no : 89 ) 21a - A5 Biotin - TDHQAARKS ( SEQ ID no : 90 ) 2la—A6 Biotin—TDHQMARKS ( SEQ ID no : 10 ) 2la—A7 Biotin—TDHQMAAKS ( SEQ ID no : 91 ) 21a - A8 Biotin - TDHQMARAS ( SEQ ID no : 92 ) 21a - A9 Biotin - TDHQMARKA ( SEQ ID no : 93 ) . [ 0115 ] The pattern for U251 and PC3 binding are gener - . a11y simi1ar. Rep1acement of the aspartic acid ( D ) residue in the sec0nd p0sition 0f the 9 - mer increased binding 0f the peptide to ce1ls and replacement of the Q residue in the fourth p0sition produced a 1arge increase of peptide binding t0 cells. Acc0rdingly , the peptide TAHAMARKS ( SEQ lD NO : 11 ) should be more actiVe than the parent peptide TDHQMARKS ( SEQ lD NO : 10 ) . Based on the binding of the peptide TDHAMARKS , this binding may be equal t0 0r greater than ch10rotoxin itself. [ 0116 ] Based upon this ﬁnding , it is expected that a Variant peptide of ch10rotoxin of the sequence be1ow may be stronger in binding than the natiVe chlorotoxin polypeptide. ( SEQ ID no : 12 ) MCMPCFTTAHAMARKCDDCCGGKGRCKCYGPQCLCR. EXAMPLE 11. [ 0117 ] ln order to compare binding of the sh0rt scorpion toxins , the regions homologous to peptide 21 of small toxin and probable t0xin LQH - 8 / 6 Were synthesized and biotiny - 1ated for analysis in the ch10rotoxin binding assay. ( See Table 6 for amino acid sequences of the peptides ) . US 2006 / 0166892 A1. TABLE 6. . Scorpion Toxin Peptide 21. . Chl0r0t0Xin TTDHQMARKS ( SEQ ID NO : 82 ) . Small TOxin TTDPQMSKK ( SEQ ID NO : 94 ) . Probable TOXin LQH—8 / 6 TTDQQMTKK ( SEQ ID NO : 95 ) . . [ 0118 ] As shoWn in FIG. 11 , and in accordance with preVious results , ch10rot0xin exhibited signiﬁcant binding in PC3 human prostate cancer cells ( 22l.93% of background leVels ) and peptide 21 binding paralleled that 0f chlorotoxin ( 232.50% of background leVe1s ) . Additiona1ly , peptide 21 of sma11 t0xin peptide ( 21 ST ) and peptide 21 0f probab1e toxin LQH - 8 / 6 ( 21LQ ) demonstrated binding leVels equiValent to that 0f full - length chl0rot0xin and chl0r0t0xin peptide 21 ( 225.26% and 242.32% , respectiVely ) . Furtherm0re , a negatiVe peptide containing amino acids 26 - 35 of ch1orotoxin ( SEQ lD NO : 1 ) exhibited binding leVels comparable to background ( 110% ) . Similar results were obtained in D54 g1i0b1ast0ma ce1ls ( data not shown ) . [ 0119 ] The results fr0m this study using the chlor0toxin binding assay indicate that ch10r0t0xin , sma11 toxin peptide , and pr0bab1e toxin LQH - 8 / 6 bind simi1ar1y to human cancer cells in Vitro Table 7 beloW highlights amino acids conserVed Within the putatiVe primary binding d0main ( amino acids 7 - 16 ) 0f the three toxin peptides. TABLE 7. . Scorpion toxin Amino acid sequence. . Chl0rOtOxin TTDHQMARKC ( SEQ ID NO : 6l ) . Small toxin peptide TTDPQMSKK ( SEQ ID NO : 94 ) . Probable toxin LQH—8 / 6 TTDQQMTKK ( SEQ ID NO : 95 ) . . EXAMPLE 12. [ 0120 ] The purpose 0f this experiment Was to determine if the pro1iferation D54MG Glioblastoma cel1s , as measured by 3H - thymidine uptake , is effected by Peptide 21 , a segment of the full chlorotoxin sequence. The sequence of peptide 21 and its relati0n t0 chl0r0t0xin is sh0Wn in the sequence be1ow : . ChlorOtOxin : MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR. Peptide 2l : TTDHQMARK ( SEQ ID NO : 82 ) . Jul 27 , 2006. Peptide 21 ( SEQ ID NO : 82 ) has been identiﬁed in seVeral other reports as haVing binding and biological actiVity comparable to the fall length ch10rotoxin. [ 0121 ] D54MG ce11s Were plated in a 24 we1l plate at 100 , 000 cel1s / ml / We11 using ﬁVe roWs of four We11s for each concentration. The cells were alloWed to adhere in n0rmal media for tWenty - four hours at 37° C. and 5% carbon dioxide. TM - 70l Was diluted to a 1 nM stock solution and added to each roW at the concentrations of 0 , 20 , 80 , l60 and 320 nM. [ 0122 ] The cells and peptide 2l Were all0Wed to incubate for 24 hours at 37° C. and 5% carbon dioxide. After twenty - four hours , the cells Were rinsed tWo times With Warm PBS. N0rma1 media Was added back t0 the ce11s at 1 ml / We1l. One uCi 0f 3H - thymidine Was added t0 each Wel1 ( 1 111 0f 1 mCi / ml 3H - thymidine t0 each Wel1 ) . The plate Was incubated for tWo hours at 37° C. The media and thymidine Were remoVed and the Wells Were rinsed With ice - cold phosphate - buﬂered saline three times. T0 each We11 Was added 1 m1 of 0.3 N NaOH. The p1ate Was incubated in the 37° C. incubat0r f0r thirty minutes. Each Well of 0.3 N NaOH Was pipetted up and doWn three t0 four times and remoVed from the p1ate and the so1uti0n Was p1aced in scintillati0n Vials for counting. Scintillati0n ﬂuid at four times the am0unt of sample was added t0 the Vials ( 4 ml ) . Each Via1 Was counted 0n the scinti11ation c0unter f0r 0ne minute. The results are sh0Wn in Table 8 and FIG. 12. The data demonstrates that peptide 21 behaVes similar t0 ch10 - rotoxin , in that the uptake of 3H - thymidine decreases in a d0es - dependent manner. This data als0 indicates that peptide 21 has an eﬂect on the DNA synthesis in these ce11s. TABLE 8. . [ Peptide 21 ] ( nM ) 3H - Thymidine uptake 1 SD ( CPM ) . . 0 8645 i 1218 1218 20 7795 I 634 634 80 7412 I 630 630 160 6983 i 329 329. 320 5782 I 886 886. . [ 0123 ] Alth0ugh the present inVenti0n has been described in detail with reference to examples aboVe , it is underst0od that Various modiﬁcations can be made Without departing from the spirit of the inVention. Accordingly , the inVention is 1imited 0nly by the f0lloWing c1aims. A1l cited patents , patent applications and publications referred to in this application are herein incorporated by reference in their entirety. . SEQUENCE LISTING. <l60> NUMBER OF SEQ ID NOS : 95. <210> SEQ ID NO 1 <211> LENGTH : 36. <212> TYPE : PRT <2l3> ORGANISM : Leiurus quinquestriatus. US 2006 / 0166892 A1 20. —continued. Jul 27 , 2006. . <220> FEATURE : <22l> NAME / KEY : misc_feature <223> OTHER INFORMATION : Chlorotoxin. <400> SEQUENCE : 1. Met Cys Met Pro Cys Phe Thr Thr Asp His Gln Met Ala Arg Lys Cys 1 5 10 15. Asp Asp Cys Cys Gly Gly Lys Gly Arg Gly Lys Cys Tyr Gly Pro Gln 20 25 30. Cys Leu Cys Arg 35. <2l0> SEQ ID NO 2. <2ll> LENGTH : 42. <2l2> TYPE : PRT. <213> ORGANISM : Leiurus quinquestriatus. <400> SEQUENCE : 2. His His His His His His Met Cys Met Pro Cys Phe Thr Thr Asp His 1 5 lO l5. Gln Met Ala Arg Lys Cys Asp Asp Cys Cys Gly Gly Lys Gly Arg Gly 20 25 30. Lys Cys Tyr Gly Pro Gln Cys Leu Cys Arg 35 40. <2l0> SEQ ID NO 3. <2ll> LENGTH : 37. <212> TYPE : PRT. <213> ORGANISM : Leiurus quinquestriatus. <400> SEQUENCE : 3. Tyr Met Cys Met Pro Cys Phe Thr Thr Asp His Gln Met Ala Arg Lys 1 5 10 15. Cys Asp Asp Cys Cys Gly Gly Lys Gly Arg Gly Lys Cys Tyr Gly Pro 20 25 3O. Gln Cys Leu Cys Arg 35. <2lO> SEQ ID NO 4. <2ll> LENGTH : 39. <212> TYPE : PRT. <2l3> ORGANISM : Leiurus quinquestriatus. <400> SEQUENCE : 4. Tyr Ser Tyr Met Cys Met Pro Cys Phe Thr Thr Asp His Gln Met Ala 1 5 10 15. Arg Lys Cys Asp Asp Cys Cys Gly Gly Lys Gly Arg Gly Lys Cys Tyr 20 25 30. Gly Pro Gln Cys Leu Cys Arg 35. <2l0> SEQ ID NO 5. <211> LENGTH : 36. <212> TYPE : PRT. <2l3> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Chlorotoxin Variant. <400> SEQUENCE : 5. US 2006 / 0166892 A1 21. —continued. Jul 27 , 2006. . Met Cys Met Pro Cys Phe Thr Thr Asp His Gln Met Ala Arg Lys Cys 1 5 lO l5. Asp Asp Cys Cys Gly Gly Lys Gly Arg Gly Lys Cys Phe Gly Pro Gln 20 25 30. Cys Leu Cys Arg 35. <2l0> SEQ ID NO 6. <211> LENGTH : 35. <2l2> TYPE : PRT. <213> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Chlorotoxin variant. <400> SEQUENCE : 6. Arg Cys Lys Pro Cys Phe Thr Thr Asp Pro Gln Met Ser Lys Lys Cys l 5 lO lS. Ala Asp Cys Cys Gly Gly Lys Gly Lys Gly Lys Cys Tyr Gly Pro Gln 20 25 3O. Cys Leu Cys 35. <2l0> SEQ ID NO 7. <211> LENGTH : 38. <2l2> TYPE : PRT. <2l3> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Chlorotoxin variant. <400> SEQUENCE : 7. Arg Cys Ser Pro Cys Phe Thr Thr Asp Gln Gln Met Thr Lys Lys Cys 1 5 10 15. Tyr Asp Cys Cys Gly Gly Lys Gly Lys Gly Lys Cys Tyr Gly Pro Gln 20 25 3O. Cys Ile Cys Ala Pro Tyr 35. <2l0> SEQ ID NO 8. <211> LENGTH : 7. <212> TYPE : PRT. <2l3> ORGANISM : Leiurus quinquestriatus. <220> FEATURE : . <22l> NAME / KEY : misc_feature. <223> OTHER INFORMATION : Derivative of Chlorotoxin : amino acid residues 23 - 29. <400> SEQUENCE : 8. Lys Gly Arg Gly Lys Ser Tyr 1 5. <2l0> SEQ ID NO 9. <2ll> LENGTH : 7. <2l2> TYPE : PRT. <213> ORGANISM : Leiurus quinquestriatus. <220> FEATURE : . <221> NAME / KEY : misc , feature. <223> OTHER INFORMATION : Derivative of Chlorotoxin : amino acid residues 8—l4. <400> SEQUENCE : 9. Thr Asp His Gln Met Ala Arg 1 5. US 2006 / 0166892 A1. 22. —continued. Jul 27 , 2006. . <210> <2ll> <2l2> <213> <220> <223>. <400>. SEQ ID NO lO. LENGTH : 9. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin alpha peptide. SEQUENCE : lO. Thr Asp His Gln Met Ala Arg Lys Ser. 1. <210> <2ll> <2l2> <213> <220> <223>. <400>. <2l0> <211> <2l2> <2l3> <220> <223>. <400>. <2l0> <211> <2l2> <213> <220> <223> <220>. 5. SEQ ID NO 11. LENGTH : 9. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Variant of chlorotoxin alpha peptide. SEQUENCE : ll. Thr Ala His Ala Met Ala Arg Lys Ser 1 5. SEQ ID NO l2. LENGTH : 36. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Variant peptide of chlorotoxin. SEQUENCE : lZ. Met Cys Met Pro Cys Phe Thr Thr Ala His Ala Met Ala Arg Lys Cys l 5 lO lS Asp Asp Cys Cys Gly Gly Lys Gly Arg Cys Lys Cys Tyr Gly Pro Gln 20 25 3O Cys Leu Cys Arg 35. SEQ ID NO l3. LENGTH : 9. TYPE : PRT. ORGANISM : Artiﬁcial. FEATURE : . OTHER INFORMATION : motif for chlorotoxin derivatives FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223>. <400>. <210> <2ll> <212> <213>. <400>. LOCATION : ( 1 ) . ( 9 ) . OTHER INFORMATION : Xaa at position 3 = Asn or Glu ; Xaa at position 4 = Ala , Arg , Asn , Asp , Cys , Gln , Glu , Gly , His , Ile , Leu , Lys , Met , Phe , Ser , . Thr , Trp , Tyr or Val ; Xaa at position 5 = Asn or Gln ; Xaa at. position 7 = Ser or Thr ; Xaa at position 8 = His , Lys or Arg. SEQUENCE : l3. Thr Thr Xaa Xaa Xaa Met Xaa Xaa Lys 1 5. SEQ ID NO l4. LENGTH : 9. TYPE : PRT. ORGANISM : Leiurus quinquestriatus. SEQUENCE : l4. Thr Thr Asp His Gln Met Ala Arg Lys 1 5. US 2006 / 0166892 A1. 23. —continued. Jul 27 , 2006. . <2l0> <211> <2l2> <2l3>. <400>. <210> <2ll> <2l2> <213> <220> <223> <220>. SEQ ID NO l5. LENGTH : 35. TYPE : PRT. ORGANISM : Mesobuthus tamulus. SEQUENCE : lS. Arg Cys Lys Pro Cys Phe Thr Thr Asp Pro Gln Met Ser Lys Lys Cys l 5 lO lS Ala Asp Cys Cys Gly Gly Lys Gly Lys Gly Lys Cys Tyr Gly Pro Gln 2O 25 3O Cys Leu Cys 35. SEQ ID NO l6. LENGTH : 34. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Small Toxin consensus sequence FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 2 ) . ( 2 ) OTHER INFORMATION : Xaa can be Met or Lys FEATURE : . <221> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 9 ) . ( 9 ) OTHER INFORMATION : Xaa can be His or Pro FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223>. <400>. <210> <2ll> <2l2> <213>. <400>. <2l0> <211> <2l2> <2l3> <220> <223> <220>. LOCATION : ( 16 ) . ( 16 ) OTHER INFORMATION : Xaa can be Asp or Ala. SEQUENCE : l6. Cys Xaa Pro Cys Phe Thr Thr Asp Xaa Gln Met Ala Lys Lys Cys Xaa. l 5 10 lS. Asp Cys Cys Gly Gly Lys Gly Lys Gly Lys Cys Tyr Gly Pro Gln Cys 20 25 30. Leu Cys. SEQ ID NO l7. LENGTH : 38. TYPE : PRT. ORGANISM : Leiurus quinquestriatus. SEQUENCE : l7. Arg Cys Ser Pro Cys Phe Thr Thr Asp Gln Gln Met Thr Lys Lys Cys. 1 5 10 15 Tyr Asp Cys Cys Gly Gly Lys Gly Lys Gly Lys Cys Tyr Gly Pro Gln 20 25 30 Cys Ile Cys Ala Pro Tyr 35 SEQ ID NO lB LENGTH : 34 TYPE : PRT ORGANISM : Artiﬁcial sequence FEATURE : OTHER INFORMATION : Probable Toxin LQH 8 / 6 consensus sequence. FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 2 ) . ( 2 ) OTHER INFORMATION : Xaa can be Met or Ser FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 9 ) . ( 9 ) OTHER INFORMATION : Xaa can be His or Gln FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222>. LOCATION : ( 12 ) . ( 12 ) . US 2006 / 0166892 A1 Jul. 27 , 2006 24. —continued. . <223> OTHER INFORMATION : Xaa can be Ala or Thr <220> FEATURE : . <221> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( l6 ) . ( l6 ) . <223> OTHER INFORMATION : Xaa can be Asp or Tyr. <400> SEQUENCE : lB. Cys Xaa Pro Cys Phe Thr Thr Asp Xaa Gln Met Xaa Lys Lys Cys Xaa. l 5 lO lS. Asp Cys Cys Gly Gly Lys Gly Lys Gly Lys Cys Tyr Gly Pro Gln Cys 20 25 3O. Ile Cys. <2l0> SEQ ID NO l9. <211> LENGTH : 61. <2l2> TYPE : PRT. <2l3> ORGANISM : Mesobuthus martensii. <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 1 ) . ( 61 ) . <223> OTHER INFORMATION : Xaa can be any amino acid. <400> SEQUENCE : 19. Met Lys Phe Leu Tyr Gly Ile Val Phe Ile Ala Leu Phe Leu Thr Val l 5 lO lS. Met Phe Ala Thr Gln Thr Asp Gly Cys Gly Pro Cys Phe Thr Thr Asp. 20 25 30 Ala Asn Met Ala Arg Lys Cys Arg Glu Cys Cys Gly Gly Ile Gly Xaa 35 4O 45 Xaa Lys Cys Phe Gly Pro Gln Cys Leu Cys Asn Arg Ile 50 55 6O. <2lO> SEQ ID NO 20. <2ll> LENGTH : 34. <212> TYPE : PRT. <213> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Chinese Scorpion consensus sequence <220> FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> LOCATION : ( 2 ) . ( 2 ) . <223> OTHER INFORMATION : Xaa can be Met or Gly <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 9 ) . ( 9 ) . <223> OTHER INFORMATION : Xaa can be His or Ala <220> FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> LOCATION : ( 16 ) . ( 16 ) . <223> OTHER INFORMATION : Xaa can be Asp or Arg <220> FEATURE : . <221> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 22 ) . ( 22 ) . <223> OTHER INFORMATION : Xaa can be Lys or Ile <220> FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> LOCATION : ( 24 ) . ( 25 ) . <223> OTHER INFORMATION : Xaa can be any amino acid. <400> SEQUENCE : 20. Cys Xaa Pro Cys Phe Thr Thr Asp Xaa Asn Met Ala Arg Lys Cys Xaa. 1 5 10 15. Asp Cys Cys Gly Gly Xaa Gly Xaa Xaa Lys Cys Phe Gly Pro Gln Cys 2O 25 3O. Leu Cys. <2l0> SEQ ID NO 2l. <2ll> LENGTH : 59. <212> TYPE : PRT. <2l3> ORGANISM : Mesobuthus martensii. US 2006 / 0166892 A1. 25. —continued. . SEQUENCE : 2l. Met Lys Phe Leu Tyr Gly Ile Val Phe Ile Ala. Leu Phe Leu Thr Val. Jul 27 , 2006. l 5 lO lS Met Phe Ala Thr Gln Thr Asp Gly Cys Gly Pro Cys Phe Thr Thr Asp 20 25 3O Ala Asn Met Ala Arg Lys Cys Arg Glu Cys Cys Gly Gly Ile Gly Lys 35 4O 45 Cys Phe Gly Pro Gln Cys Leu Cys Asn Arg Ile 5O 55. <2l0> SEQ ID NO 22. <2ll> LENGTH : 32. <2l2> TYPE : PRT. <213> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Chinese Scorpion consensus sequence. <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 2 ) . ( 2 ) . <223> OTHER INFORMATION : Xaa can be Met or Gly. <220> FEATURE : . <221> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 9 ) . ( 9 ) . <223> OTHER INFORMATION : Xaa can be His or Ala. <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 16 ) . ( 16 ) . <223> OTHER INFORMATION : Xaa can be Asp or Arg. <220> FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> LOCATION : ( 22 ) . ( 22 ) . <223> OTHER INFORMATION : Xaa can be Lys or Ile. <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 25 ) . ( 25 ) . <223> OTHER INFORMATION : Xaa can be Gly or Cys. <220> FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> LOCATION : ( 26 ) . ( 26 ) . <223> OTHER INFORMATION : Xaa can be Lys or Phe. <220> FEATURE : . <221> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 27 ) . ( 27 ) . <223> OTHER INFORMATION : Xaa can be Cys or Gly. <220> FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> LOCATION : ( 28 ) . ( 28 ) . <223> OTHER INFORMATION : Xaa can be Tyr or Pro. <220> FEATURE : . <221> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 29 ) . ( 29 ) . <223> OTHER INFORMATION : Xaa can be Gly or Gln. <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 30 ) . ( 30 ) . <223> OTHER INFORMATION : Xaa can be Pro or Cys. <220> FEATURE : . <221> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 31 ) . ( 31 ) . <223> OTHER INFORMATION : Xaa can be Gln or Leu. <400> SEQUENCE : 22. Cys Xaa Pro Cys Phe Thr Thr Asp Xaa Asn Met Ala Arg Lys Cys Xaa l 5 lO lS. Asp Cys Cys Gly Gly Xaa Gly Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys 20 25 3O <2lO> SEQ ID NO 23 <2ll> LENGTH : 37 <212> TYPE : PRT <2l3> ORGANISM : Mesobuthus eupeus. US 2006 / 0166892 A1. 26. —continued. Jul 27 , 2006. . <220> <22l> <222> <223>. <400>. <2l0> <211> <2l2> <2l3> <220> <223> <220> <221> <222> <223> <220> <22l> <222> <223> <220> <221> <222> <223> <220> <22l> <222> <223>. <400>. <2l0> <211> <212> <2l3>. <400>. <210> <2ll> <2l2> <213> <220> <223> <220>. FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 1 ) . ( 37 ) . OTHER INFORMATION : Xaa can be any amino acid. SEQUENCE : 23. Met Cys Met Pro Cys Phe Thr Thr Asp Pro Asn Met Ala Asn Lys Cys. 1 5 10 15 Arg Asp Cys Cys Gly Gly Xaa Gly Lys Xaa Lys Cys Phe Gly Pro Gln 20 25 3O Cys Leu Cys Asn Arg 35 SEQ ID NO 24 LENGTH : 35 TYPE : PRT ORGANISM : Artiﬁcial sequence FEATURE : OTHER INFORMATION : Insect toxin I5 consensus sequence. FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( lO ) . ( 10 ) . OTHER INFORMATION : Xaa can be His or Pro FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 14 ) . ( 14 ) . OTHER INFORMATION : Xaa can be Arg or Asn FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( l7 ) . ( 17 ) . OTHER INFORMATION : Xaa can be Asp or Arg FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 23 ) . ( 26 ) . OTHER INFORMATION : Xaa can be any amino acid. SEQUENCE : 24. Met Cys Met Pro Cys Phe Thr Thr Asp Xaa Asn Met Ala Xaa Lys Cys 1 5 10 15 Xaa Asp Cys Cys Gly Gly Xaa Gly Lys Xaa Lys Cys Phe Gly Pro Gln 20 25 30 Cys Leu Cys 35. SEQ ID NO 25. LENGTH : 35. TYPE : PRT. ORGANISM : Mesobuthus eupeus. SEQUENCE : 25. Met Cys Met Pro Cys Phe Thr Thr Asp Pro Asn Met Ala Asn Lys Cys l 5 lO l5 Arg Asp Cys Cys Gly Gly Gly Lys Lys Cys Phe Gly Pro Gln Cys Leu 2O 25 3O Cys Asn Arg 35. SEQ ID NO 26. LENGTH : 33. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Insect toxin I5 consensus sequence FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 10 ) . ( 10 ) OTHER INFORMATION : Xaa can be His or Pro FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222>. LOCATION : ( 14 ) . ( 14 ) . US 2006 / 0166892 A1. 27. —continued. Jul 27 , 2006. . <223> OTHER INFORMATION : Xaa <220> FEATURE : . <221> NAME / KEY : MISC_FEATURE <222> LOCATION : ( l7 ) . ( l7 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC ; FEATURE <222> LOCATION : ( 23 ) . ( 24 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( 26 ) . ( 26 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC ; FEATURE <222> LOCATION : ( 27 ) . ( 27 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( 28 ) . ( 28 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( 29 ) . ( 29 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( 30 ) . ( 30 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( 3l ) . ( 3l ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( 32 ) . ( 32 ) <223> OTHER INFORMATION : Xaa. <400> SEQUENCE : 26. can. can. can. can. can. can. can. can. can. can. be Arg or Asn. be Asp or Arg. be Lys or Gly. be Gly or Cys. be Lys or Phe. be Cys or Gly. be Tyr or Pro. be Gly or Gln. be Pro or Cys. be Gln or Leu. Met Cys Met Pro Cys Phe Thr Thr Asp Xaa Asn Met Ala Xaa Lys Cys. 1 5. 10. 15. Xaa Asp Cys Cys Gly Gly Xaa Xaa Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa. 20 Cys. <2lO> SEQ ID NO 27 <2ll> LENGTH : 38 <212> TYPE : PRT. <213> ORGANISM : Mesobuthus eupeus. <220> FEATURE : <221> NAME / KEY : MISC_FEATURE <222> LOCATION : ( l ) . ( 38 ) . 25. <223> OTHER INFORMATION : Xaa can be any amino acid. <400> SEQUENCE : 27. 30. Met Cys Met Pro Cys Phe Thr Thr Arg Pro Asp Met Ala Gln Gln Cys. l 5. lO. lS. Arg Ala Cys Cys Lys Gly Xaa Xaa Arg Gly Lys Cys Phe Gly Pro Gln. 20. Cys Leu Cys Gly Tyr Asp. 35. <210> SEQ ID NO 28 <2ll> LENGTH : 35 <212> TYPE : PRT. 25. <213> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . 30. <223> OTHER INFORMATION : Insectotoxin I1 consensus sequence. <220> FEATURE : <22l> NAME / KEY : MISC ; FEATURE <222> LOCATION : ( 9 ) . ( 9 ) . <223> OTHER INFORMATION : Xaa can be Asp or Arg. US 2006 / 0166892 A1. 28. —continued. Jul 27 , 2006. . <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( 10 ) . ( 10 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <221> NAME / KEY : MISC_FEATURE <222> LOCATION : ( ll ) . ( ll ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC ; FEATURE <222> LOCATION : ( 14 ) . ( 14 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( l5 ) . ( l5 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC ; FEATURE <222> LOCATION : ( l7 ) . ( l7 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC , FEATURE <222> LOCATION : ( 18 ) . ( 18 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( 2l ) . ( 2l ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC , FEATURE <222> LOCATION : ( 23 ) . ( 24 ) <223> OTHER INFORMATION : Xaa. <400> SEQUENCE : 28. can. can. can. can. can. can. can. can. be His or Pro. be Gln or Asp. be Arg or Gln. be Lys or Gln. be Asp or Arg. be Asp or Ala. be Gly or Lys. be any amino acid. Met Cys Met Pro Cys Phe Thr Thr Xaa Xaa Xaa Met Ala. l 5. 10. Xaa Xaa Cys Cys Xaa Gly Xaa Xaa Arg Gly Lys Cys Phe. 20 Cys Leu Cys 35. <2l0> SEQ ID NO 29 <211> LENGTH : 36 <2l2> TYPE : PRT. <2l3> ORGANISM : Mesobuthus eupeus. <400> SEQUENCE : 29. 25. Met Cys Met Pro Cys Phe Thr Thr Arg Pro Asp Met Ala. l 5. lO. Arg Ala Cys Cys Lys Gly Arg Gly Lys Cys Phe Gly Pro. 20 Cys Gly Tyr Asp 35. <2l0> SEQ ID NO 30 <2ll> LENGTH : 33 <212> TYPE : PRT. 25. <2l3> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . Xaa Xaa Cys lS. Gly Pro Gln. 3O. Gln Gln Cys l5. Gln Cys Leu. 30. <223> OTHER INFORMATION : Insectotoxin I1 consensus sequence. <220> FEATURE : <22l> NAME / KEY : MISCiFEATURE <222> LOCATION : ( 9 ) . ( 9 ) . <223> OTHER INFORMATION : Xaa can be Asp or Arg. <220> FEATURE : <221> NAME / KEY : MISC_FEATURE <222> LOCATION : ( l0 ) . ( l0 ) . <223> OTHER INFORMATION : Xaa can be His or Pro. <220> FEATURE : <22l> NAME / KEY : MISC ; FEATURE <222> LOCATION : ( 11 ) . ( 11 ) . <223> OTHER INFORMATION : Xaa can be Gln or Asp. US 2006 / 0166892 A1. 29. —continued. Jul 27 , 2006. . <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( 14 ) . ( 14 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <221> NAME / KEY : MISC_FEATURE <222> LOCATION : ( l5 ) . ( l5 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC ; FEATURE <222> LOCATION : ( 17 ) . ( 17 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( l8 ) . ( l8 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC ; FEATURE <222> LOCATION : ( 2l ) . ( 2l ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC , FEATURE <222> LOCATION : ( 26 ) . ( 26 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( 27 ) . ( 27 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC , FEATURE <222> LOCATION : ( 28 ) . ( 28 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( 29 ) . ( 29 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC , FEATURE <222> LOCATION : ( 30 ) . ( 30 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <221> NAME / KEY : MISC_FEATURE <222> LOCATION : ( 31 ) . ( 31 ) <223> OTHER INFORMATION : Xaa <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE <222> LOCATION : ( 32 ) . ( 32 ) <223> OTHER INFORMATION : Xaa. <400> SEQUENCE : 30. Met Cys Met Pro Cys Phe Thr Thr Xaa Xaa Xaa Met Ala Xaa Xaa Cys. 1 5. Xaa Xaa Cys Cys Xaa Gly Lys Gly Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa. 20 Cys. <2l0> SEQ ID NO 31 <2ll> LENGTH : 37 <212> TYPE : PRT. <2l3> ORGANISM : Mesobuthus eupeus. <220> FEATURE : <221> NAME / KEY : MISC_FEATURE <222> LOCATION : ( l ) . ( 37 ) . can. can. can. can. can. can. can. can. can. can. can. can. be Arg or Gln. be Lys or Gln. be Asp or Arg. be Asp or Arg. be Gly or Lys. be Gly or Cys. be Lys or Phe. be Cys or Gly. be Tyr or Pro. be Gly or Gln. be Pro or Cys. be Gln or Leu. 10. 25 30. <223> OTHER INFORMATION : Xaa can be any amino acid. <400> SEQUENCE : 3l. Met Cys Met Pro Cys Phe Thr Thr Asp Pro Asn Met Ala Lys Lys Cys. l 5. Arg Asp Cys Cys Gly Gly Asn Gly Xaa Xaa Lys Cys Phe Gly Pro Gln. 20 Cys Leu Cys Asn Arg 35. lO. 25 3O. US 2006 / 0166892 A1 Jul 27 , 2006 30. —continued. . <2l0> SEQ ID NO 32. <211> LENGTH : 35. <2l2> TYPE : PRT. <2l3> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Insectotoxin 15A consensus sequence <220> FEATURE : . <221> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( l0 ) . ( l0 ) . <223> OTHER INFORMATION : Xaa can be His or Pro <220> FEATURE : . <22l> NAME / KEY : MISC ; FEATURE. <222> LOCATION : ( 17 ) . ( 17 ) . <223> OTHER INFORMATION : Xaa can be Asp or Arg <220> FEATURE : . <221> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 23 ) . ( 23 ) . <223> OTHER INFORMATION : Xaa can be Lys or Asn <220> FEATURE : . <22l> NAME / KEY : MISC ; FEATURE. <222> LOCATION : ( 25 ) . ( 26 ) . <223> OTHER INFORMATION : Xaa can be any amino acid. <400> SEQUENCE : 32. Met Cys Met Pro Cys Phe Thr Thr Asp Xaa Asn Met Ala Lys Lys Cys 1 5 lO lS Xaa Asp Cys Cys Gly Gly Xaa Gly Xaa Xaa Lys Cys Phe Gly Pro Gln 20 25 30 Cys Leu Cys 35. <2l0> SEQ ID NO 33. <21l> LENGTH : 35. <212> TYPE : PRT. <2l3> ORGANISM : Mesobuthus eupeus. <400> SEQUENCE : 33. Met Cys Met Pro Cys Phe Thr Thr Asp Pro Asn Met Ala Lys Lys Cys. l 5 lO lS Arg Asp Cys Cys Gly Gly Asn Gly Lys Cys Phe Gly Pro Gln Cys Leu 20 25 3O Cys Asn Arg 35. <210> SEQ ID NO 34. <211> LENGTH : 33. <2l2> TYPE : PRT. <213> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Insectotoxin l5A consensus sequence <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 10 ) . ( 10 ) . <223> OTHER INFORMATION : Xaa can be His or Pro <220> FEATURE : . <221> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( l7 ) . ( 17 ) . <223> OTHER INFORMATION : Xaa can be Asp or Arg <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 23 ) . ( 23 ) . <223> OTHER INFORMATION : Xaa can be Lys or Asn <220> FEATURE : . <221> NAME / KEY : MISC , FEATURE. <222> LOCATION : ( 26 ) . ( 26 ) . <223> OTHER INFORMATION : Xaa can be Gly or Cys <220> FEATURE : . <22l> NAME / KEY : MISC ; FEATURE. <222> LOCATION : ( 27 ) . ( 27 ) . <223> OTHER INFORMATION : Xaa can be Lys or Phe <220> FEATURE : . US 2006 / 0166892 A1. 31. —continued. Jul 27 , 2006. . <221> <222> <223> <220> <22l> <222> <223> <220> <221> <222> <223> <220> <22l> <222> <223> <220>. NAME / KEY : MISC_FEATURE. LOCATION : ( 28 ) . ( 28 ) . OTHER INFORMATION : Xaa can be Cys or Gly FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 29 ) . ( 29 ) . OTHER INFORMATION : Xaa can be Tyr or Pro FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 30 ) . ( 30 ) . OTHER INFORMATION : Xaa can be Gly or Gln FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 3l ) . ( 31 ) OTHER INFORMATION : Xaa can be Pro or Cys FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223>. <400>. <2l0> <211> <2l2> <2l3> <220>. LOCATION : ( 32 ) . ( 32 ) OTHER INFORMATION : Xaa can be Gln or Leu. SEQUENCE : 34. Met Cys Met Pro Cys Phe Thr Thr Asp Xaa Asn Met Ala Lys Lys Cys. l 5 lO lS. Xaa Asp Cys Cys Gly Gly Xaa Gly Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 3O. Cys. SEQ ID NO 35. LENGTH : 37. TYPE : PRT. ORGANISM : Androctonus mauretanicus FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223>. <400>. <2l0> <211> <212> <2l3> <220> <223> <220>. LOCATION : ( 1 ) . ( 37 ) OTHER INFORMATION : Xaa can be any amino acid. SEQUENCE : 35. Cys Gly Pro Cys Phe Thr Thr Asp Pro Tyr Thr Glu Ser Lys Cys Ala. 1 5 10 15 Thr Cys Cys Gly Gly Xaa Xaa Arg Gly Lys Cys Val Gly Pro Gln Cys 20 25 30 Leu Cys Asn Arg Ile 35 SEQ ID NO 36 LENGTH : 34 TYPE : PRT ORGANISM : Artiﬁcial sequence FEATURE : OTHER INFORMATION : Neurotoxin P2 consensus sequence. FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 2 ) . ( 2 ) OTHER INFORMATION : Xaa can be Met or Gly FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> <223> <220>. LOCATION : ( 9 ) . ( 9 ) OTHER INFORMATION : Xaa can be His or Pro FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 10 ) . ( 10 ) OTHER INFORMATION : Xaa can be Gln or Tyr FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 11 ) . ( 11 ) OTHER INFORMATION : Xaa can be Met or Thr FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 12 ) . ( 12 ) OTHER INFORMATION : Xaa can be Ala or Glu FEATURE : . <22l> NAME / KEY : MISC_FEATURE. US 2006 / 0166892 A1. 32. —continued. Jul 27 , 2006. . <222> <223> <220>. LOCATION : ( 13 ) . ( 13 ) OTHER INFORMATION : Xaa can be Arg or Ser FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 16 ) . ( 16 ) OTHER INFORMATION : Xaa can be Asp or Ala FEATURE : . <221> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 17 ) . ( 17 ) OTHER INFORMATION : Xaa can be Asp or Thr FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 22 ) . ( 23 ) OTHER INFORMATION : Xaa can be any amino acid FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223>. <400>. <210> <2ll> <212> <2l3>. <400>. <2l0> <211> <2l2> <2l3> <220> <223> <220>. LOCATION : ( 28 ) . ( 28 ) OTHER INFORMATION : Xaa can be Tyr or Val. SEQUENCE : 36. Cys Xaa Pro Cys Phe Thr Thr Asp Xaa Xaa Xaa Xaa. l 5 lO. Xaa Cys Cys Gly Gly Xaa Xaa Arg Gly Lys Cys Xaa 20 25. Leu Cys. SEQ ID NO 37. LENGTH : 35. TYPE : PRT. ORGANISM : Androctonus mauretanicus. SEQUENCE : 37. Cys Gly Pro Cys Phe Thr Thr Asp Pro Tyr Thr Glu l 5 lO Thr Cys Cys Gly Gly Arg Gly Lys Cys Val Gly Pro 20 25 Asn Arg Ile 35. SEQ ID NO 38. LENGTH : 32. TYPE : PRT. ORGANISM : Artiﬁcial sequence FEATURE : . Xaa Lys Cys Xaa lS Gly Pro Gln Cys 3O. Ser Lys Cys Ala lS Gln Cys Leu Cys 3O. OTHER INFORMATION : Neurotoxin P2 consensus sequence. FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 2 ) . ( 2 ) OTHER INFORMATION : Xaa can be Met or Gly FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> <223> <220>. LOCATION : ( 9 ) . ( 9 ) OTHER INFORMATION : Xaa can be His or Pro FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 10 ) . ( 10 ) OTHER INFORMATION : Xaa can be Gln or Tyr FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> <223> <220>. LOCATION : ( 11 ) . ( 11 ) OTHER INFORMATION : Xaa ca be Met or Thr FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 12 ) . ( 12 ) OTHER INFORMATION : Xaa can be Ala or Glu FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 13 ) . ( 13 ) OTHER INFORMATION : Xaa can be Arg or Ser FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222>. LOCATION : ( l6 ) . ( 16 ) . US 2006 / 0166892 A1. 33. —continued. Jul 27 , 2006. . <223> <220> <221> <222> <223> <220> <22l> <222> <223> <220> <22l> <222> <223> <220> <22l> <222> <223> <220> <22l> <222> <223> <220> <221> <222> <223> <220> <22l> <222> <223> <220>. OTHER INFORMATION : Xaa can be Asp or Ala FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 17 ) . ( 17 ) . OTHER INFORMATION : Xaa can be Asp or Thr FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 25 ) . ( 25 ) . OTHER INFORMATION : Xaa can be Gly or Cys FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 26 ) . ( 26 ) . OTHER INFORMATION : Xaa can be Lys or Val FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 27 ) . ( 27 ) . OTHER INFORMATION : Xaa can be Cys or Gly FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 28 ) . ( 28 ) . OTHER INFORMATION : Xaa can be Tyr or Pro FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 29 ) . ( 29 ) . OTHER INFORMATION : Xaa can be Gly or Gln FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 30 ) . ( 30 ) OTHER INFORMATION : Xaa can be Pro or Cys FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223>. <400>. <210> <2ll> <212> <2l3> <220> <223> <220>. LOCATION : ( 31 ) . ( 31 ) OTHER INFORMATION : Xaa can be Gln or Leu. SEQUENCE : 38. Cys Xaa Pro Cys Phe Thr Thr Asp Xaa Xaa Xaa Xaa Xaa Lys Cys Xaa. l 5 lO l5. Xaa Cys Cys Gly Gly Lys Gly Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys 20 25 3O. SEQ ID NO 39. LENGTH : 37. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Toxin consensus sequence FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> <223>. <400>. <210> <2ll> <2l2> <213> <220> <223> <220>. LOCATION : ( 1 ) . ( 37 ) OTHER INFORMATION : Xaa can be any amino acid. SEQUENCE : 39. Met Cys Met Pro Cys Phe Thr Thr Asp Pro Asn Met Ala Lys Lys Cys. l 5 lO l5 Arg Asp Cys Cys Gly Gly Lys Gly Xaa Xaa Lys Cys Phe Gly Pro Gln 2O 25 3O Cys Leu Cys Asn Arg 35 SEQ ID NO 40 LENGTH : 35 TYPE : PRT ORGANISM : Artiﬁcial sequence FEATURE : OTHER INFORMATION : Toxin consensus sequence FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 3 ) . ( 3 ) OTHER INFORMATION : Xaa can be Met , Lys or Ser FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222>. LOCATION : ( 10 ) . ( 10 ) . US 2006 / 0166892 A1. 34. —continued. Jul 27 , 2006. . <223> <220>. OTHER INFORMATION : Xaa can be His , Pro , or Gln FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223>. <400>. <210> <2ll> <2l2> <213> <220> <223>. <400>. <210> <2ll> <212> <213> <220> <223>. <400>. <2l0> <211> <2l2> <213> <220> <223>. <400>. <2l0> <211> <2l2> <2l3> <220> <223>. <400>. <2lO> <2ll> <212> <2l3>. LOCATION : ( 17 ) . ( 17 ) OTHER INFORMATION : Xaa can be Asp , Ala , or Tyr. SEQUENCE : 40. Arg Cys Xaa Pro Cys Phe Thr Thr Asp Xaa Gln Met Ser Lys Lys Cys l 5 lO lS Xaa Asp Cys Cys Gly Gly Lys Gly Lys Gly Lys Cys Tyr Gly Pro Gln 2O 25 3O Cys Leu Cys 35. SEQ ID NO 41. LENGTH : 35. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Toxin consensus sequence. SEQUENCE : 4l. Met Cys Met Pro Cys Phe Thr Thr Asp Pro Asn Met Ala Arg Lys Cys l 5 lO lS Arg Asp Cys Cys Gly Gly Arg Gly Lys Cys Phe Gly Pro Gln Cys Leu 20 25 3O Cys Asn Arg 35. SEQ ID NO 42. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence FEATURE : . OTHER INFORMATION : Pep8—Cth. SEQUENCE : 42. Cys Gly Gly Lys Gly Arg Gly Lys Cys Tyr l 5 lO. SEQ ID NO 43. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence FEATURE : . OTHER INFORMATION : Pep8 - SCXl , BUTSI. SEQUENCE : 43. Cys Gly Gly Lys Gly Lys Gly Lys Cys Tyr l 5 lO. SEQ ID NO 44. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence FEATURE : . OTHER INFORMATION : Pep8—AF079059_2. SEQUENCE : 44. Cys Gly Gly Ile Gly Lys Cys Phe Gly Pro. 1 5 10 SEQ ID NO 45. LENGTH : l2. TYPE : PRT. ORGANISM : Artiﬁcial sequence. US 2006 / 0166892 A1. 35. —continued. Jul 27 , 2006. . <220> <223> <220> <22l> <222> <223>. <400>. <210> <2ll> <2l2> <213> <220> <223> <220> <22l> <222> <223>. <400>. <210> <2ll> <2l2> <213> <220> <223>. <400>. <2l0> <211> <2l2> <2l3> <220> <223>. <400>. <2l0> <211> <212> <2l3> <220> <223> <220>. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 8 consensus sequence FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 4 ) . ( 4 ) . OTHER INFORMATION : Xaa can be Lys or Ile. SEQUENCE : 45. Cys Gly Gly Xaa Gly Arg Gly Lys Cys Phe Gly Pro 1 5 lO. SEQ ID NO 46. LENGTH : 6. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 8 consensus sequence FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 4 ) . ( 4 ) . OTHER INFORMATION : Xaa can be Lys or Ile. SEQUENCE : 46. Cys Gly Gly Xaa Gly Lys 1 5. SEQ ID NO 47. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Pep8—NJO361 sequence. SEQUENCE : 47. Cys Gly Gly Gly Lys Lys Cys Phe Gly Pro 1 5 lO. SEQ ID NO 48. LENGTH : l2. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 8 consensus sequence. SEQUENCE : 48. Cys Gly Gly Lys Gly Lys Gly Lys Cys Phe Gly Pro 1 5 lO. SEQ ID NO 49. LENGTH : 6. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 8 consensus sequence FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223>. <400>. <2l0> <211> <2l2>. LOCATION : ( 4 ) . ( 5 ) OTHER INFORMATION : Xaa can be Lys or Gly. SEQUENCE : 49 Cys Gly Gly Xaa Xaa Lys. 1 5. SEQ ID NO 50 LENGTH : lO TYPE : PRT. US 2006 / 0166892 A1 36. —continued. Jul 27 , 2006. . <213> ORGANISM : Artiﬁcial sequence <220> FEATURE : <223> OTHER INFORMATION : Pep8—SCX1_BUTEU sequence. <400> SEQUENCE : 50. Cys Lys Gly Arg Gly Lys Cys Phe Gly Pro 1 5 lO. <2l0> SEQ ID NO 5l. <211> LENGTH : 12. <2l2> TYPE : PRT. <213> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Chlorotoxin Peptide 8 consensus sequence <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 3 ) . ( 3 ) . <223> OTHER INFORMATION : Xaa can be Gly or Cys. <400> SEQUENCE : 5l. Cys Gly Xaa Lys Gly Arg Gly Lys Cys Phe Gly Pro 1 5 lO. <2l0> SEQ ID NO 52. <211> LENGTH : 6. <2l2> TYPE : PRT. <213> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Chlorotoxin Peptide 8 consensus sequence <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 2 ) . ( 2 ) . <223> OTHER INFORMATION : Xaa can be Gly or Lys. <400> SEQUENCE : 52. Cys Xaa Gly Lys Gly Lys 1 5. <2l0> SEQ ID NO 53. <2ll> LENGTH : 10. <2l2> TYPE : PRT. <213> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Pep8 - SCX5 , BUTEU sequence. <400> SEQUENCE : 53. Cys Gly Gly Asn Gly Lys Cys Phe Gly Pro 1 5 lO. <2l0> SEQ ID NO 54. <211> LENGTH : 12. <2l2> TYPE : PRT. <213> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Chlorotoxin Peptide 8 consensus sequence <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 4 ) . ( 4 ) . <223> OTHER INFORMATION : Xaa can be Lys or Asn. <400> SEQUENCE : 54 Cys Gly Gly Xaa Gly Arg Gly Lys Cys Phe Gly Pro. 1 5 10. <210> SEQ ID NO 55 <2ll> LENGTH : 6. US 2006 / 0166892 A1. Jul 27 , 2006. . <212> <2l3> <220> <223> <220>. 37 —continued TYPE : PRT ORGANISM : Artiﬁcial sequence FEATURE : OTHER INFORMATION : Chlorotoxin Peptide 8 consensus sequence. FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223>. <400>. <2l0> <211> <2l2> <2l3> <220> <223>. <400>. <210> <2ll> <212> <2l3> <220> <223> <220>. LOCATION : ( 4 ) . ( 4 ) OTHER INFORMATION : Xaa can be Lys or Asn. SEQUENCE : 55. Cys Gly Gly Xaa Gly Lys 1 5. SEQ ID NO 56. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Pep8—SCXP_ANDMA sequence. SEQUENCE : 56. Cys Gly Gly Arg Gly Lys Cys Val Gly Pro 1 5 lO. SEQ ID NO 57. LENGTH : l2. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 8 consensus sequence FEATURE : . <221> NAME / KEY : MISC , FEATURE. <222> <223>. <400>. <2l0> <2ll> <212> <2l3> <220> <223>. <400>. <210> <2ll> <212> <2l3> <220> <223> <220>. LOCATION : ( 10 ) . ( 10 ) OTHER INFORMATION : Xaa can be Tyr or Val. SEQUENCE : 57. Cys Gly Gly Lys Gly Arg Gly Lys Cys Xaa Gly Pro 1 5 lO. SEQ ID NO 58. LENGTH : 6. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 8 consensus sequence. SEQUENCE : 58. Cys Gly Gly Lys Gly Lys 1 5. SEQ ID NO 59. LENGTH : l2. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 8 consensus sequence FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> <223>. <400>. <2l0>. LOCATION : ( 4 ) . ( 5 ) OTHER INFORMATION : Xaa can be Lys or Gly. SEQUENCE : 59 Cys Gly Gly Xaa Xaa Arg Gly Lys Cys Phe Gly Pro. 1 5 lO. SEQ ID NO 60. US 2006 / 0166892 A1. 38. Jul 27 , 2006. . <211> <2l2> <213> <220> <223>. <400>. <2l0> <21l> <2l2> <2l3> <220> <223>. <400>. <210> <2ll> <212> <213> <220> <223>. <400>. <210> <211> <2l2> <213> <220> <223> <220>. —continued LENGTH : lO TYPE : PRT ORGANISM : Artiﬁcial sequence FEATURE : OTHER INFORMATION : Chlorotoxin Peptide 8 consensus sequence. SEQUENCE : 60. Cys Gly Gly Lys Gly Lys Cys Phe Gly Pro 1 5 lO. SEQ ID NO 6l. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 21 sequence. SEQUENCE : 6l. Thr Thr Asp His Gln Met Ala Arg Lys Cys l 5 lO. SEQ ID NO 62. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Pep21 - SCX1 - BUTSI sequence. SEQUENCE : 62. Thr Thr Asp Pro Gln Met Ser Lys Lys Cys l 5 lO. SEQ ID NO 63. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 21 consensus sequence FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223>. <400>. <210> <2ll> <212> <213> <220> <223>. <400>. <210> <211> <2l2> <213> <220> <223> <220>. LOCATION : ( 4 ) . ( 4 ) OTHER INFORMATION : Xaa can be His or Pro. SEQUENCE : 63. Thr Thr Asp Xaa Gln Met Ala Lys Lys Cys 1 5 10. SEQ ID NO 64. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Pep21—SCX8_LEIQH sequence. SEQUENCE : 64. Thr Thr Asp Gln Gln Met Thr Lys Lys Cys l 5 lO. SEQ ID NO 65. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 2l consensus sequence FEATURE : . <22l> NAME / KEY : MISC_FEATURE. US 2006 / 0166892 A1. 39. —continued. Jul 27 , 2006. . <222> <223> <220> <22l> <222> <223>. <400>. <210> <2ll> <2l2> <213> <220> <223>. <400>. <2l0> <21l> <212> <2l3> <220> <223> <220>. LOCATION : ( 4 ) . ( 4 ) . OTHER INFORMATION : Xaa can be His or Gln FEATURE : . NAME / KEY : MISC_FEATURE. LOCATION : ( 7 ) . ( 7 ) . OTHER INFORMATION : Xaa can be Ala or Thr. SEQUENCE : 65. Thr Thr Asp Xaa Gln Met Xaa Lys Lys Cys l 5 lO. SEQ ID NO 66. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Pep2l—AF079059_2 sequence. SEQUENCE : 66. Thr Thr Asp Ala Asn Met Ala Arg Lys Cys l 5 lO. SEQ ID NO 67. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 21 consensus sequence FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223>. <400>. <2l0> <211> <2l2> <2l3> <220> <223>. <400>. <2l0> <211> <212> <2l3> <220> <223> <220>. LOCATION : ( 4 ) . ( 4 ) OTHER INFORMATION : Xaa can be His or Ala. SEQUENCE : 67. Thr Thr Asp Xaa Asn Met Ala Arg Lys Cys l 5 lO. SEQ ID NO 68. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Pep2l—JN0361 sequence. SEQUENCE : 68. Thr Thr Asp Pro Asn Met Ala Asn Lys Cys l 5 lO. SEQ ID NO 69. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 2l consensus sequence FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 4 ) . ( 4 ) OTHER INFORMATION : Xaa can be either His or Pro FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223>. <400>. LOCATION : ( 8 ) . ( 8 ) OTHER INFORMATION : Xaa can be Arg or Asn. SEQUENCE : 69. Thr Thr Asp Xaa Asn Met Ala Xaa Lys Cys 1 5 10. US 2006 / 0166892 A1. 40. —continued. Jul 27 , 2006. . <2l0> <211> <2l2> <2l3> <220> <223>. <400>. <2lO> <2ll> <212> <2l3> <220> <223> <220>. SEQ ID NO 70. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Pep2l—SCX1_BUTEU sequence. SEQUENCE : 70. Thr Thr Arg Pro Asp Met Ala Gln Gln Cys 1 5 10. SEQ ID NO 7l. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 21 consensus sequence FEATURE : . <221> NAME / KEY : MISC , FEATURE. <222> <223> <220>. LOCATION : ( 3 ) . ( 3 ) OTHER INFORMATION : Xaa can be Asp or Arg FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 4 ) . ( 4 ) OTHER INFORMATION : Xaa can be His or Pro FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> <223> <220>. LOCATION : ( 5 ) . ( 5 ) OTHER INFORMATION : Xaa can be Gln or Asp FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223> <220>. LOCATION : ( 8 ) . ( 8 ) OTHER INFORMATION : Xaa can be Arg or Gln FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> <223>. <400>. <210> <2ll> <212> <213> <220> <223>. <400>. <210> <2ll> <2l2> <213> <220> <223> <220>. LOCATION : ( 9 ) . ( 9 ) OTHER INFORMATION : Xaa can be Lys or Gln. SEQUENCE : 7l. Thr Thr Xaa Xaa Xaa Met Ala Xaa Xaa Cys 1 5 10. SEQ ID NO 72. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Pep21 - SCX5_BUTEU sequence. SEQUENCE : 72. Thr Thr Asp Pro Asn Met Ala Lys Lys Cys 1 5 10. SEQ ID NO 73. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Chlorotoxin Peptide 2l consensus sequence FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> <223>. <400>. LOCATION : ( 4 ) . ( 4 ) OTHER INFORMATION : Xaa can be His or Pro. SEQUENCE : 73. Thr Thr Asp Xaa Asn Met Ala Lys Lys Cys 1 5 10. Us 2006 / O166892 A1 Jul 27 , 2006 41. —continued. . <2l0> SEQ ID NO 74. <211> LENGTH : 10. <2l2> TYPE : PRT. <2l3> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Pep2l—SCXP_ANDMA sequence. <400> SEQUENCE : 74. Thr Thr Asp Pro Tyr Thr Glu Ser Lys Cys 1 5 10. <2lO> SEQ ID NO 75. <2ll> LENGTH : 10. <212> TYPE : PRT. <2l3> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Chlorotoxin Peptide 21 consensus sequence <220> FEATURE : . <221> NAME / KEY : MISC , FEATURE. <222> LOCATION : ( 4 ) . ( 4 ) . <223> OTHER INFORMATION : Xaa can be His or Pro <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 5 ) . ( 5 ) . <223> OTHER INFORMATION : Xaa can be Gln or Tyr <220> FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> LOCATION : ( 6 ) . ( 6 ) . <223> OTHER INFORMATION : Xaa can be Met or Thr <220> FEATURE : . <22l> NAME / KEY : MISC_FEATURE. <222> LOCATION : ( 7 ) . ( 7 ) . <223> OTHER INFORMATION : Xaa can be Ala or Glu <220> FEATURE : . <22l> NAME / KEY : MISC , FEATURE. <222> LOCATION : ( 8 ) . ( 8 ) . <223> OTHER INFORMATION : Xaa can be Arg or Ser. <400> SEQUENCE : 75. Thr Thr Asp Xaa Xaa Xaa Xaa Xaa Lys Cys 1 5 10. <2lO> SEQ ID NO 76. <2ll> LENGTH : 10. <212> TYPE : PRT. <213> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Chlorotoxin Peptide 21 consensus sequence. <400> SEQUENCE : 76. Thr Thr Asp Pro Asn Met Ala Lys Lys Cys 1 5 10. <2l0> SEQ ID NO 77. <2ll> LENGTH : 7. <2l2> TYPE : PRT. <213> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Chlorotoxin derivative STP—1. <400> SEQUENCE : 77 Thr Asp Pro Gln Met Ser Arg. 1 5. <2l0> SEQ ID NO 78 <211> LENGTH : 10 <2l2> TYPE : PRT. US 2006 / 0166892 A1. 42. —continued. Jul 27 , 2006. . <213> <220> <223>. <400>. <210> <211> <2l2> <213> <220> <223>. <400>. <2lO> <21l> <212> <2l3> <220> <223>. <400>. <210> <2ll> <212> <213> <220> <223>. <400>. <210> <211> <2l2> <213> <220> <223>. <400>. <2l0> <211> <2l2> <2l3> <220> <223>. <400>. <2l0>. ORGANISM : Artiﬁcial sequence FEATURE : OTHER INFORMATION : Peptide 8 sequences. SEQUENCE : 78. Gly Gly Lys Gly Arg Gly Lys Ser Tyr Gly l 5 lO. SEQ ID NO 79. LENGTH : 9. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Peptide 8a sequence. SEQUENCE : 79. Gly Lys Gly Arg Gly Lys Ser Tyr Gly l 5. SEQ ID NO 80. LENGTH : 8. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Peptide 8b sequence. SEQUENCE : 80. Lys Gly Arg Gly Lys Ser Tyr Gly l 5. SEQ ID NO 81. LENGTH : 7. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Peptide 8c sequence. SEQUENCE : 81. Gly Arg Gly Lys Ser Tyr Gly l 5. SEQ ID NO 82. LENGTH : lO. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Peptide 21 sequence. SEQUENCE : 82. Thr Thr Asp His Gln Met Ala Arg Lys Ser 1 5 lO. SEQ ID NO 83. LENGTH : 8. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Peptide 2lb sequence. SEQUENCE : 83 Asp His Gln Met Ala Arg Lys Ser. 1 5. SEQ ID NO 84. US 2006 / 0166892 A1. Jul 27 , 2006. . <211> <2l2> <213> <220> <223>. <400>. <2l0> <21l> <2l2> <2l3> <220> <223>. <400>. <210> <2ll> <212> <213> <220> <223>. <400>. <210> <211> <2l2> <213> <220> <223>. <400>. <2l0> <211> <2l2> <2l3> <220> <223>. <400>. <2l0> <2ll> <212> <2l3> <220> <223>. <400>. 43 —continued LENGTH : 7 TYPE : PRT ORGANISM : Artiﬁcial sequence FEATURE : OTHER INFORMATION : Peptide 21c sequence. SEQUENCE : 84. His Gln Met Ala Arg Lys Ser 1 5. SEQ ID NO 85. LENGTH : 6. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Peptide 21d sequence. SEQUENCE : 85. Gln Met Ala Arg Lys Ser 1 5. SEQ ID NO 86. LENGTH : 9. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Peptide 21a - A1 sequence. SEQUENCE : 86. Ala Asp His Gln Met Ala Arg Lys Ser 1 5. SEQ ID NO 87. LENGTH : 9. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Peptide 21a—A2 sequence. SEQUENCE : 87. Thr Ala His Gln Met Ala Arg Lys Ser 1 5. SEQ ID NO 88. LENGTH : 9. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Peptide 2la—A3 sequence. SEQUENCE : 88. Thr Asp Ala Gln Met Ala Arg Lys Ser 1 5. SEQ ID NO 89. LENGTH : 9. TYPE : PRT. ORGANISM : Artiﬁcial sequence. FEATURE : . OTHER INFORMATION : Peptide 21a - A4 sequence. SEQUENCE : 89. Thr Asp His Ala Met Ala Arg Lys Ser 1 5. US 2006 / 0166892 A1 44. —continued. Jul 27 , 2006. . <2l0> SEQ ID NO 90. <211> LENGTH : 9. <2l2> TYPE : PRT. <2l3> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Peptide 21a—A5 sequence. <400> SEQUENCE : 90. Thr Asp His Gln Ala Ala Arg Lys Ser 1 5. <2l0> SEQ ID NO 9l. <2ll> LENGTH : 9. <212> TYPE : PRT. <213> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Peptide 2la—A7 sequence. <400> SEQUENCE : 9l. Thr Asp His Gln Met Ala Ala Lys Ser 1 5. <2l0> SEQ ID NO 92. <21l> LENGTH : 9. <2l2> TYPE : PRT. <2l3> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Peptide 21a—A8 sequence. <400> SEQUENCE : 92. Thr Asp His Gln Met Ala Arg Ala Ser 1 5. <2l0> SEQ ID NO 93. <2ll> LENGTH : 9. <2l2> TYPE : PRT. <213> ORGANISM : Artiﬁcial sequence. <220> FEATURE : . <223> OTHER INFORMATION : Peptide 21a - A9 sequence. <400> SEQUENCE : 93. Thr Asp His Gln Met Ala Arg Lys Ala l 5. <2l0> SEQ ID NO 94. <2ll> LENGTH : 9. <212> TYPE : PRT. <213> ORGANISM : Mesobuthus tamulus sindicus. <220> FEATURE : . <223> OTHER INFORMATION : GenBank Accesssion No. Pl5229 , small toxin. <400> SEQUENCE : 94. Thr Thr Asp Gln Gln Met Ser Lys Lys 1 5. <2l0> SEQ ID NO 95. <211> LENGTH : 9. <212> TYPE : PRT. <213> ORGANISM : Leiurus quinquestriatus hebraeu. <220> FEATURE : . <223> OTHER INFORMATION : GenBank Accession No. P55966 , probable toxin. US 2006 / 0166892 A1. Jul 27 , 2006. —continued. . <400> SEQUENCE : 95. Thr Thr Asp Pro Gln Met Ser Lys Lys 1 5. . 1. An iso1ated po1ypeptide c0mprising a subunit 0f chlorotoxin 0r a related sc0rpion toxin , wherein the p0lypeptide speciﬁcally binds to a cancer cell. 2. The isolated polypeptide of claim 1 Wherein the p01ypeptide c0mprises an amino acid sequence se1ected from the group consisting of SEQ ID NO : 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 and 14. 3. The isolated polypeptide of claim 1 Wherein the polypeptide comprises the amino acid sequence TTXlX2X3MX4X5K ( SEQ ID NO : 13 ) , wherein. ( a ) X1 is an acidic amin0 acid se1ected fr0m the gr0up c0nsisting of aspartic acid and g1utamic acid ; . ( b ) X2 is an amino acid se1ected from the group c0nsisting of alanine , arginine , asparagine , aspartic acid , cysteine , glutamine , glutamic acid , glycine , histidine , is0leucine , 1eucine , 1ysine , pro1ine , methi0nine , pheny1a1anine , serine , thre0nine , trypt0phan , tyr0sine and Va1ine ; . ( c ) X3 is an amide amino acid se1ected from the gr0up c0nsisting of asparagine and glutamine ; . ( d ) X4 is an amino acid se1ected from the group c0nsisting of serine , threonine and alanine ; and. ( e ) X5 is a basic amino acid selected from the group. c0nsisting of histine , lysine and arginine. 4. The isolated polypeptide of claim 3 Wherein the amino acid sequence is SEQ ID NO : 14 ( TTDHQMARK ) . 5. The iso1ated po1ypeptide of c1aim 3 Wherein the amino acid sequence is SEQ ID NO : 94 ( TTDQQMTKK ) . 6. The is0lated p0lypeptide of claim 3 wherein in the amino acid sequence is SEQ ID NO : 95 ( TTDPQMSKK ) . 7. The is01ated po1ypeptide of c1aim 1 Wherein the cancer ce11 is fr0m a cancer se1ected from the group c0nsisting of lung cancer , bone cancer , liVer cancer , pancreatic cancer , skin cancer , cancer 0f the head 0r neck , cutane0us or intraocular melanoma , uterine cancer , oVarian cancer , rectal cancer , cancer of the ana1 region , stomach cancer , co10n cancer , breast cancer , uterine cancer , carcinoma of the fallopian tubes , carcinoma of the endometrium , carcinoma of the cerVix , carcin0ma 0f the Vagina , carcin0ma of the VulVa , Hodgkins Disease , cancer of the esophagus , cancer of the sma11 intestine , cancer of the endocrine system , cancer of the thyroid g1and , cancer of the parathyroid gland , cancer of the adrenal gland , sarcoma of soft tissue , cancer of the urethra , cancer of the penis , pro state cancer , chronic or acute leukemia , lymphocytic lymphomas , cancer of the bladder , cancer 0f the kidney or ureter , rena1 ce11 carcinoma , carcinoma of the renal pe1Vis , neop1asms of the centra1 nerVous system ( CNS ) , neuroectodermal cancer , spinal axis tumors , glioma , meningioma and pituitary adenoma. 8. A fusion polypeptide comprising the polypeptide of c1aim 1 11nked to a second p01ypeptide. 9. The fusi0n po1ypeptide 0f claim 8 Wherein the sec0nd po1ypeptide comprises a cancer ce11 - binding domain which binds speciﬁcally of an epitope expressed only by a cancer cell. 10. The fusi0n po1ypeptide of c1aim 9 wherein the sec0nd p0lypeptide is an antib0dy or fragment thereof. 11. The fusion p0lypeptide 0f claim 8 Wherein the sec0nd p01ypeptide c0mprises a stabi1izati0n domain which preVent degradati0n 0f the fusi0n p0lypeptide. 12. The fusi0n p01ypeptide of c1aim 8 Wherein the sec0nd p01ypeptide is se1ected from the gr0up c0nsisting 0f p01y - histidine , human serum albumin and human transferrin. 13. The p01ypeptide 0f claim 1 Wherein the p01ypeptide is 11nked to a cytot0xic agent. 14. The polypeptide of claim 13 Wherein the cytotoxic agent is se1ected fr0m the gr0up c0nsisting 0f ge1onin , ricin , sap0nin , pseudon0mas ex0toxin , p0keweed antiViral pr0 - tein , diphtheria t0xin and c0mplement pr0teins. 15. The p01ypeptide 0f claim 1 Wherein the p01ypeptide is 18beled. 16. The po1ypeptide of claim 15 Wherein the label is. l31II. 17. A composition comprising the p01ypeptide of c1aim 1. 18. A method 0f treating a disease characterized by abn01ma1 ce11 pro1iferation in a mamma1 c0mprising administering the composition of claim 17. 19. The method of claim 18 , Wherein the disease is cancer. 20. The method 0f claim l9 Wherein the cancer is selected fr0m the gr0up c0nsisting of lung cancer , bone cancer , liVer cancer , pancreatic cancer , skin cancer , cancer of the head or neck , cutaneous 0r intra0cu1ar me1anoma , uterine cancer , 0Varian cancer , recta1 cancer , cancer 0f the ana1 regi0n , stomach cancer , colon cancer , breast cancer , uterine cancer , carcinoma of the fall0pian tubes , carcin0ma 0f the endometrium , carcinoma of the cerVix , carcinoma of the Vagina , carcinoma of the Vu1Va , Hodgkins Disease , cancer of the esophagus , cancer of the smal1 intestine , cancer of the endocrine system , cancer of the thyroid gland , cancer of the parathyroid gland , cancer 0f the adrenal gland , sarc0ma 0f soft tissue , cancer of the urethra , cancer of the penis , prostate cancer , chr0nic 0r acute 1eukemia , 1ymph0cytic1ymphomas , cancer of the bladder , cancer of the kidney or ureter , rena1 cell carcinoma , carcinoma of the renal pelVis , neoplasms of the central nerVous system ( CNS ) , neuroectodermal cancer , spinal axis tumors , glioma , meningioma and pituitary adenoma. 21. A method 0f treating a disease in a mammal characterized by abnormal cel1 pro1iferation comprising administering a composition consisting essentially of chlorotoxin or a related scorpion toxin. 22. The method of claim 2l Wherein the composition is suitable f0r use in humans. 23. The method of c1aim 21 wherein the amount of ch10rot0xin administered is less than about 0.1 mg / kg b0dy Weight. 24. The method of claim 21 wherein the amount of ch10rotoxin administered is less than about 0.05 mg / kg body Weight. US 2006 / 0166892 A1. 25. The method of claim 21 Wherein the amount of ch10rotoxin administered comprises betWeen about 0.01 ug / kg body Weight to about 0.1 mg / kg body Weight. 26. The method 0f claim 21 wherein the amount of ch10rot0xin administered comprises betWeen ab0ut 0.1 ug / kg body Weight to about 0.05 mg / kg body Weight. 27. The method of claim 21 Wherein the amount of ch10rotoxin administered comprises betWeen about 0.1 ug / kg b0dy Weight to ab0ut 0.1 mg / kg body Weight. 28. The method 0f claim 21 wherein the amount of ch10rot0xin administered comprises betWeen about 0.1 ug / kg body Weight to about 1.0 mg / kg body Weight. 29. The method 0f c1aim 21 wherein the amount of ch10rot0xin administered comprises betWeen ab0ut 0.1 ug / kg body weight to ab0ut 2.0 mg / kg body Weight. 30. The method of claim 2l Wherein the mammal is a human. 31. The method of c1aim 21 Wherein the disease is cancer. 32. The meth0d 0f c1aim 31 Wherein the cancer is se1ected from the group consisting of lung cancer , b0ne cancer , 1iVer cancer , pancreatic cancer , skin cancer , cancer of the head or neck , cutane0us 0r intraocular melanoma , uterine cancer , oVarian cancer , recta1 cancer , cancer 0f the ana1 region , stomach cancer , c0l0n cancer , breast cancer , uterine cancer , carcin0ma 0f the fall0pian tubes , carcin0ma of the end0metrium , carcin0ma 0f the cerVix , carcin0ma 0f the Vagina , carcinoma of the VulVa , Hodgkins Disease , cancer of the esophagus , cancer 0f the sma11 intestine , cancer 0f the end0crine system , cancer 0f the thyr0id g1and , cancer 0f the parathyr0id gland , cancer 0f the adrenal gland , sarc0ma of soft tissue , cancer 0f the urethra , cancer of the penis , pro state. Jul 27 , 2006. cancer , chronic or acute leukemia , lymphocytic lymphomas , cancer of the bladder , cancer of the kidney or ureter , renal cell carcinoma , carcinoma of the renal pelVis , neop1asms of the centra1 nerV0us system ( CNS ) , neuroect0dermal cancer , spina1 axis tumors , glioma , meningioma and pituitary adenoma. 33. An iso1ated nucleic acid m0lecule encoding the polypeptide of claim l. 34. The isolated nucleic acid molecule of claim 33 Wherein the nuc1eic acid molecule is 0perably 11nked to 0ne or m0re expressi0n contro1 e1ements. 35. A Vector comprising an isolated nucleic acid m0lecule 0f claim 34. 36. A host cell comprising the Vector of claim 35. 37. The h0st ce11 0f c1aim 36 Wherein the host is se1ected from the gr0up 00nsisting of prokary0tic h0st ce1ls and eukaryotic host ce1ls. 38. A meth0d for pr0ducing a polypeptide comprising culturing the host cell of claim 37 under conditi0ns in which the po1ypeptide enc0ded by said nuc1eic acid m01ecu1e is expressed. 39. The meth0d of claim 38 Wherein the host ce11 is selected fr0m the group c0nsisting 0f pr0karyotic h0st cells and eukaryotic host cells. 40. An iso1ated p0lypeptide produced by the method 0f c1aim 39. 41. A method f0r pr0ducing a po1ypeptide c0mprising chemical1y synthesizing the p0lypeptide of c1aim 1. >i< >l< $ $ >i<